amfAR, THE FOUNDATION FOR AIDS RESEARCH, IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH.
A MESSAGE FROM THE CHAIRMAN

LAST YEAR THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) reported that the number of new HIV infections in the U.S. each year was 40 percent higher than was previously thought. Now that’s pretty shocking... and it shows that we’re losing the battle against AIDS in America.

Here’s another statistic that should serve as a wake-up call: For every person we put on treatment, three more get infected with HIV. At this rate, AIDS is going to bankrupt many countries around the world that are trying to cover the cost of treatment for all who need it.

The fact is that the only way we’ll prevail over this epidemic is by finding a vaccine or a cure for AIDS. And that won’t happen unless we support the scientists who are doing the research that can make it happen.

amfAR’s research has been behind many of the major breakthroughs in treatment and prevention of the past 25 years, and we’ll continue to lead the way until we bring an end to this epidemic.

But we can’t do it alone. I hope you’ll stay with us, and I thank you for your generous support.

— KENNETH COLE
Chairman of the Board

amfAR’s research has been behind many of the major breakthroughs in treatment and prevention of the past 25 years, and we’ll continue to lead the way until we bring an end to this epidemic.

— KENNETH COLE
A MESSAGE FROM THE CEO

WELCOME TO AMFAR’S 2008 ANNUAL REPORT. This year we’ve chosen a new, interactive format for three good reasons: It’s cost effective. It’s environmentally responsible. And it’s an excellent vehicle for showing you, and all of our supporters, the breadth of our accomplishments and the scope of our work.*

By clicking on the maps in this report, you’ll get a snapshot of the projects we undertook in 2008. We supported biochemists in San Francisco and infectious disease specialists in China, prevention advocates in Cameroon and virologists in Amsterdam. We deployed our resources where the needs were clearly defined and not being met by others.

Our mission to end AIDS through innovative research is infused with an unshakeable commitment to human rights—to battling the stigma and discrimination that continue to undermine effective responses to the epidemic around the world.

amfAR has always been at the nexus of research and public policy. We work with lawmakers as well as scientists to ensure that policies are informed and guided by what the science tells us. That’s the only way they can be effective. And as you will see in this report, we have made some promising advances in creating, reshaping and implementing policies that will advance our mission and respect the rights of people around the world.

There is much to be done in the months and years ahead, but I am personally filled with a renewed sense of hope that in my lifetime we will indeed find a cure for AIDS. It is the breakthroughs made by amfAR research—research that is supported by you—that gives me this hope. With your continuing support, we will bring hope—and much more—to the 33 million people living with HIV/AIDS worldwide.

I look forward to your thoughts on our progress. And I thank you for your continuing support.

— KEVIN ROBERT FROST
Chief Executive Officer

*For interactive web-based version of this Annual Report, go to ar.amfar.org.
amfAR Fellow Films Birth of HIV

Using a cutting-edge technique she pioneered, amfAR research fellow Dr. Nolwenn Jouvenet became the first scientist ever to witness and record the birth of HIV virus particles. Just a few months after receiving one of amfAR’s Mathilde Krim Fellowships in Basic Biomedical Research, Dr. Jouvenet published her groundbreaking findings in the May 2008 issue of the prestigious journal Nature. Her work could point to new ways of attacking HIV.

“We didn’t know how long it would take for a virus to be made—a few seconds, minutes, or hours. But to assemble all the different pieces of the virus took around 10 minutes. It’s quite astonishing.”

— Nolwenn Jouvenet, Ph.D.
Aaron Diamond AIDS Research Center
New York City

First Step Toward a Cure for AIDS?

When an HIV-positive leukemia patient needed a stem cell transplant, doctors found him a donor with a natural mutation that causes resistance to HIV. Now off anti-HIV drugs for more than two years, the patient shows no trace of HIV. In September 2008, amfAR brought some of the world’s leading AIDS researchers together for a think tank to analyze the implications of this intriguing development and to harness its potential for advancing the search for a cure.

“We need a cure for AIDS. We can’t treat our way out of this epidemic.”

— Dr. Jeffrey Laurence
Senior scientific consultant, amfAR

Nobel Prize for amfAR Grantees

In the 1980s, amfAR funded some of the earliest HIV research conducted by Professors Françoise Barré-Sinoussi and Luc Montagnier, work that was published in prestigious journals such as Science, Nature, The Lancet, and the New England Journal of Medicine. In 2008, the two researchers received the Nobel Prize in Medicine for their 1983 discovery of HIV, the virus that causes AIDS. Their discovery opened the door to understanding the biology of AIDS and learning how to treat it with antiretroviral drugs.

Curbing the Spread of HIV in Prisons

More than one in 100 adults in America is now confined in prison. With rates of infection that are more than three times higher than the general U.S. population, prisons are a breeding ground for HIV infection. In April 2008, amfAR organized a Congressional briefing that brought experts together to discuss and devise strategies for curbing the disproportionately high rates of HIV/AIDS in correctional facilities. In conjunction with the briefing, amfAR published an issue brief analyzing the factors that contribute to high rates of infection in prison and enumerating policy recommendations for tackling the problem.

“Effective HIV treatment in prisons has led to a 75 percent reduction in AIDS-related mortality.”

— HIV in Correctional Settings: Implications for Prevention and Treatment Policy
amfAR issue brief, 2008
Supporting a Global, Grassroots Response to HIV Among MSM

amfAR released a widely publicized report at the 2008 International AIDS Conference that contrasted the high rates of HIV infection among men who have sex with men (MSM) with the indifferent response and inaction of many governments. Stepping into the breach through the newly established MSM Initiative, amfAR committed more than $900,000 to grassroots organizations providing desperately needed HIV programs and services for MSM around the world. Community awards were distributed to 38 organizations in 30 developing countries in Africa, Asia and the Pacific, the Caribbean, and Latin America.

“amfAR’s MSM Initiative is working to galvanize a much needed global response to the enormous gaps in funding and services for MSM at risk of HIV/AIDS.”

—Dr. Peter Piot, executive director (retired) UNAIDS

Women, Stigma, and HIV

amfAR helped bring the plight of women with HIV/AIDS to the forefront in March 2008 by sponsoring a Congressional briefing on women, HIV, and stigma. The findings of an amfAR-sponsored survey were presented and showed persistently high levels of stigma associated with HIV-positive women. amfAR was also a co-sponsor of a continuing medical education conference in Dallas, Texas, in April that addressed the complex challenges of treating women with HIV.

Confronting the Threat of Drug Resistance

amfAR’s TREAT Asia program made good progress in 2008 in building capacity to monitor the emergence of HIV drug resistance in Asia. Eight clinical centers enrolled more than 850 patients in Hong Kong, Malaysia, the Philippines, and Thailand for a study to monitor the emergence of drug-resistant HIV in infected patients. For a surveillance study evaluating the spread of drug-resistant virus among newly infected patients, four clinical centers enrolled more than 190 patients in Hong Kong, the Philippines, and Thailand.
amfAR occupies a critically important place in AIDS research for several reasons. First, it deliberately sets out to pursue important lines of inquiry that are not being supported by others. Second, amfAR’s research program is nimble enough to rapidly switch gears, allocating resources to emerging avenues of investigation. Third, it is a reliable source of funding for both junior and well-established investigators seeking support to develop and test their innovative ideas. And by providing one or two years of seed funding, the Foundation enables researchers to accumulate the preliminary data that larger institutions such as the NIH require as a precondition for funding. This leveraging capability has proven highly successful over the past 25 years in getting bold ideas off the ground and into the clinic.

Research Priorities

In fiscal year 2008, amfAR announced 28 new grants and awards totaling $3,140,000. Among them were nine inaugural Mathilde Krim Fellowships in Basic Biomedical Research totaling more than $1 million. These awards are designed to support the work of talented young scientists who represent the next generation of AIDS research leaders.

amfAR’s grants and fellowships are selected through a rigorous process of peer review by a team of independent HIV/AIDS experts, and guided by a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS.

For now, there is no prospect of a single solution to AIDS. Many different methodologies and technologies must be developed, improved, applied, and scaled up simultaneously to bring the global epidemic under control. amfAR’s research priorities can be divided into four primary areas. The first might be called “laying the foundations” since it involves advancing the basic research studies whose results can then be applied to the other three areas: preventing HIV transmission, optimizing treatment, and pursuing HIV eradication—a cure for HIV/AIDS.

Laying the Foundations

One of the most startling scientific advances of 2008 was a groundbreaking study by Nolwenn Jouvenet, Ph.D., of the Aaron Diamond AIDS Research Center

FEATURE

Groundbreaking Findings on the Birth of HIV

In May 2008, only a few short months after receiving her Krim Fellowship, Dr. Nolwenn Jouvenet of the Aaron Diamond AIDS Research Center in New York made groundbreaking new findings concerning the birth of HIV virus particles. Dr. Jouvenet collaborated with colleagues to generate the first video footage of thousands of HIV matrix proteins coming together within infected cells to form new HIV viruses. It is the first time that the assembly of HIV—or any virus—has been observed in real time.

Her findings, published in the prestigious journal Nature, helped solve a persistent controversy in the field by establishing that viral assembly occurs near the edge of the cell, at the plasma membrane, rather than deeper within the cell, as some had previously maintained.
in New York City. In May 2008, only a few short months after receiving her Mathilde Krim Fellowship from amfAR, Dr. Jouvenet published findings in the prestigious journal *Nature* concerning the birth of HIV virus particles.

Dr. Jouvenet collaborated with colleagues to generate the first video footage of thousands of core structural proteins coming together within infected cells to form new HIV viruses. This was the first time that the assembly of HIV—or any virus—had been observed in real time (see sidebar). The technique Dr. Jouvenet pioneered has the potential to help answer outstanding questions about HIV as well as broader applications for the field of virology.

### Making Cell-Cell Contact

For more than ten years, researchers have known that retroviruses such as HIV infect target cells hundreds or even thousands of times more efficiently when an infected cell makes contact with its target and hands off the virus than when the infecting virus is free-floating. What remains incompletely understood is how the “virological synapse” that forms between an infected cell and an uninfected target cell facilitates infection. The name “synapse” in this context derives from the similarity to a neurological synapse, in which a nerve cell can communicate messages to another nerve cell situated close by.

amfAR grantee Dr. Benjamin Chen, of the Mount Sinai School of Medicine in New York, writing in the November 2007 issue of the *Journal of Virology*, described the interactions between viral and cell proteins that increase the likelihood that infection will take place when the infecting virus comes from another cell as opposed to body fluids. One upshot of this form of viral transmission is the ability of the virus to remain beyond the reach of the abundant antibodies coursing through the infected person’s blood that could easily neutralize the virus.

amfAR fellow Dr. Fedde Groot, working at the University of Oxford, United Kingdom, described another way in which cell-cell transmission of HIV works in the virus’s favor. In an article published in *Blood* in May 2008, he and colleagues explained that macrophages, one of the two main types of immune cells infected with HIV, can survive for many weeks after infection and can transmit virus particles to uninfected T cells, the other immune target of the virus, every six hours.

### Prevention Progress

Prevention research encompasses a wide range of studies, from the biomedical to the sociobehavioral. To optimize existing prevention methods, for example, it is necessary to gain an understanding of the forces that deter people from practicing safer sex, or that perpetuate misconceptions about HIV and its transmission. In the laboratory, scientists are striving to overcome the scientific obstacles that stand in the way of developing an effective vaccine or a microbicide that could be used to prevent the sexual transmission of HIV.

### Vaccines

Dr. Rogier Sanders, of the University of Amsterdam in the Netherlands, was awarded a Mathilde Krim Fellowship to support his work on an AIDS vaccine, whose development has been hampered by the difficulty of producing a protein in the lab that mimics proteins on the surface of HIV. These proteins could theoretically be used to make an AIDS vaccine.

Until now, researchers have been plagued by the difficulty of generating a three-part protein (trimer), such as that found on the surface of the virus, that is stable and has regions on its surface that would encourage the immune system to make antibodies. These antibodies could then successfully target the virus for destruction. Dr. Sanders plans to address several of the challenges that have hobbled these efforts so far. Researchers generally agree that an AIDS vaccine...
must generate neutralizing antibodies in order to prevent HIV infection.

**Overcoming Labels and Stereotypes**

In the U.S. and around the world, stigma is a major barrier to HIV prevention, care, and treatment, yet reducing it remains a low priority. amfAR grantees Dr. Robert Remien of Columbia University and Dr. Jennifer Sayles of UCLA, writing in the journal *AIDS*, highlighted the need to track the burden of stigma over time and to compare it across different regions, and do so successfully, HIV must make full-length copies of its entire genome as well as copies of each of its genes. And in order to ensure that full-length copies are made, the virus recruits a cell protein, P-TEFb, which interacts with a segment of the virus called Tat.

Dr. D’Orso plans to elucidate the precise details of the structure of these protein complexes and the process whereby Tat and P-TEFb bind together. Understanding how these molecules interact will help point towards potential therapies aimed at disrupting the vital relationship between the two proteins.

**Combatting Drug Resistance**

Several amfAR grantees are addressing the issue of HIV drug resistance, which represents a serious threat to the efficacy and sustainability of global treatment efforts. In the February 2008 issue of *AIDS Research and Human Retroviruses*, amfAR grantees Dr. Jayanta Bhattacharya and colleagues at the National AIDS Research Institute in Pune, India, described the mixing of genes from two subtypes of HIV-1, one called subtype B, common in North America, and the other called subtype C, more prevalent in Africa. Dr. Bhattacharya and colleagues reasoned that this was an example of the impact of “intercontinental and intracontinental population migration, tourism, and conglomerate enterprises.” These movements of people and populations will only increase—yet another reason to emphasize HIV prevention strategies.

Writing in the same journal, amfAR fellow Dr. Ryan Troyer of Case Western Reserve University approached the topic of drug resistance from an angle that has profound implications for the prevention of mother-to-child transmission of HIV. Dr. Troyer and associates studied HIV-positive mothers and their infants in Uganda who were either untreated or received short courses of AZT or nevirapine in an attempt to block mother-to-infant transmission of HIV. Dr. Troyer’s findings suggest that the effectiveness of nevirapine in treatment, or in prevention of mother-to-infant transmission of HIV in subsequent pregnancies, may be compromised in this region of the world by widespread drug resistance and deserves further study.

---

**FEATURE**

**NOBEL PRIZE TO FORMER amfAR GRANTEES**

Former amfAR grantees Dr. Françoise Barré-Sinoussi and Dr. Luc Montagnier shared the 2008 Nobel Prize in Medicine for their 1983 discovery of HIV, the virus that causes AIDS. amfAR is proud to count both Professor Barré-Sinoussi and Professor Montagnier among its roster of scientific researchers who have received amfAR funding.

“The impact of the work of both Françoise Barré-Sinoussi and of Luc Montagnier cannot be overstated,” said amfAR CEO Kevin Robert Frost. “In identifying the mysterious killer that we now know as HIV, these scientists opened the door to enormous scientific breakthroughs, and helped save countless lives.”

amfAR funded some of the earliest HIV research conducted by both Nobelists in the 1980s, which was published in prestigious journals such as *Science, Nature, The Lancet*, and the *New England Journal of Medicine*. They have identified some successful stigma reduction strategies. They also called for reforming laws and policies that enable discrimination against men who have sex with men, injection drug users, sex workers, and migrants.

**OPTIMIZING TREATMENT**

With 33 million people worldwide living with HIV/AIDS, it is not surprising that the benefits of research and treatment advances are unevenly distributed. Biological factors can influence responses to treatment, for example, while social circumstances can compromise access to HIV testing and medical care.

Among the amfAR-funded scientists seeking to optimize and improve HIV treatment is Dr. Ivan D’Orso of the University of California, San Francisco. Working in the lab of his mentor Dr. Alan Frankel, Dr. D’Orso was awarded a Mathilde Krim Fellowship to pursue his study of the gene transcription process that is essential for HIV to reproduce (see sidebar). In order to...
Toward HIV Eradication

Numerous amfAR-funded researchers are testing treatment strategies that might lead to the eradication of HIV. Writing in the journal Nature Medicine, amfAR fellow Nicolas Chomont, Ph.D., working with amfAR grantees Jean-Pierre Routy, M.D., and Elias Haddad, Ph.D., at the University of Montreal, offered insights into how some HIV-infected individuals are able to ward off symptoms of infection without taking anti-HIV drugs, and how their good fortune might be translated into treatments for others.

The key difference in these so-called “elite controllers” appears to lie with a special type of CD4+ T cell called the central memory cell. Compared with HIV-positive individuals who require constant antiretroviral treatment to limit virus production, or even healthy HIV-negative individuals, these cells of elite controllers are highly resistant to a variety of persistent immune stimuli that kill central memory T cells in other people.

In the Nature Medicine article, the authors show that one pathway responsible for this central memory T cell resilience involves the FOXO3a protein. Defining exactly what is different about FOXO3a-related activity in the central memory T cells of elite controllers requires further study. But the work of Chomont, Routy, Haddad, and colleagues suggests that drugs capable of inhibiting FOXO3a might facilitate the maintenance or reconstitution of a more effective immune system in HIV-positive individuals. Furthermore, these insights could also have broad benefits for many other disorders, including cancers and other viruses.

The First to Be Cured?

Will AIDS ever be cured—the virus eliminated from the body and the immune system restored? This tantalizing question was debated in an amfAR-sponsored think tank titled “Approach to Curing AIDS.”

According to a 2008 report, this feat may already have been accomplished by using a stem cell transplant (see sidebar). An HIV-positive man with leukemia received a transplant from a donor who had a genetic mutation that renders the immune cells resistant to infection by most types of HIV. The transplant was a success and the patient’s leukemia is now in complete remission. He has also remained off all anti-HIV drugs for more than two years, yet there is no detectable HIV in his body.

Could this success be replicated? Experts in clinical AIDS, stem cell transplantation, and HIV virology gathered at the two-day amfAR think tank to discuss the implications of this intriguing case. There are many reasons why this method could not be employed in the millions who are living with HIV/AIDS today, not least the significant risk of mortality associated with the procedure as well as the price tag, which runs into the hundreds of thousands of dollars. Nonetheless it has reignited hope in some quarters that a cure for HIV may be possible. And it may mark the beginning of a hopeful new chapter in the fight against AIDS.

Feature

A First Step Toward a Cure for AIDS?

Anti-HIV therapy is a lifelong commitment, and for every person placed on treatment, two to three are newly infected. Viral reservoirs—cells and tissues in which HIV remains dormant, beyond the reach of anti-HIV drugs but poised to grow at any moment—persist for the life of an infected person.

Given this context, a brief report in February 2008 by a group of physicians from Germany appeared to change everything. It described a 40-year-old man—an American working in Berlin—who had been under good control for several years using a typical cocktail of drugs known as HAART. Then he developed acute leukemia.

In an attempt to cure the leukemia, he underwent a stem cell transplant. But in his case, rather than simply using the best match among available stem cell donors, his physicians did something very clever. They also screened potential donors for a natural mutation known as delta32 CCR5. Individuals with this mutation—about 1.5 percent of the Caucasian population in America and Europe—are resistant to infection by the most common forms of HIV.

Novel Procedure Appears to Have Eliminated HIV

The patient’s stem cell transplant succeeded. All signs of leukemia and HIV disease were erased. At the very least this patient represents a functional cure: He is off all anti-HIV meds, has a normal T-cell count, and exhibits no evidence of virus.

amfAR quickly called together 10 experts for a two-day think tank to evaluate these data. In a summary statement, attendees indicated that this case does indeed represent at least a functional cure. The patient’s physician agreed to ask his patient to provide additional blood samples so that scientists attending the amfAR meeting could perform even more sensitive tests to attempt to further document that the virus has been erased from the patient.

But amfAR’s involvement doesn’t end there. While it is possible that the patient may have been cured of HIV/AIDS, the cost and risk of this procedure is prohibitive. Here further research may yield key answers.

For example, it is unknown whether the use of a delta32-CCR5 donor is essential. Perhaps the transplant procedure itself was the most important element. The potential to genetically engineer stem cells to remove CCR5 from a patient’s own stem cells also exists, and strategies to do so were discussed at the think tank. These and related issues will serve as topics for an upcoming amfAR grant cycle.
2008 Research Fellowships, Grants, & Awards

All projects listed below were supported by amfAR during the period October 1, 2007, to September 30, 2008. Grants funded during fiscal year 2008 but awarded in previous years are shown with the year of the award in parentheses.

MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH

Preventing HIV Transmission

Identification and biological characteristics of transmitted HIV-1
Brandon Keele, Ph.D.
University of Alabama at Birmingham
Birmingham, AL
$119,868

Generation of stable HIV-1 Env trimers through virus evolution
Rogier Sanders, Ph.D.
Academic Medical Center, University of Amsterdam
Amsterdam, Netherlands
$125,000

Optimizing HIV Treatment

Modulation of HIV reverse transcription and nuclear integration by TRIM5
Felipe Diaz-Griffero, Ph.D.
Dana Farber Cancer Institute
Boston, MA
$125,000

Biophysical and structural studies of the HIV integrase DNA complex
Kushol Gupta, Ph.D.
The University of Pennsylvania School of Medicine
Philadelphia, PA
$125,000

HIV Tat-mediated transfer of P-TEFb to nascent RNA and its inhibition
Ivan D’Orso, Ph.D.
University of California at San Francisco
San Francisco, CA
$125,000

Morphogenesis and storage of HIV-1 particles
Nolwenn Jouvenet, Ph.D.
Aaron Diamond AIDS Research Center
New York, NY
$125,000

Morphogenesis and storage of HIV-1 particles
Ivan D’Orso, Ph.D.
University of California at San Francisco
San Francisco, CA
$125,000

Ultrapotent inhibitors of wild-type and multi-drug resistant HIV
Bruno Marchand, Ph.D.
University of Missouri-Columbia
Columbia, MO
$125,000

Maintenance of drug resistance mutations and HIV-1 evolutionary adaptation
Morgane Rolland, Ph.D.
University of Washington
Seattle, WA
$125,000

Pursuing HIV Eradication

Novel post-transcriptional mechanisms of HIV-1 latency and reactivation
Kara Lassen, Ph.D.
Case Western Reserve University
Cleveland, OH
$125,000

Novel post-transcriptional mechanisms of HIV-1 latency and reactivation
Kara Lassen, Ph.D.
The J. David Gladstone Institutes
San Francisco, CA
$102,340 (transfer)
RESEARCH FELLOWSHIPS

Preventing HIV Transmission

The role of mental health issues in HIV acquisition among female drug users
Gail Gilchrist, Ph.D.
L’Institut Municipal d’Investigació Medica
Barcelona, Catalonia, Spain
$124,915

Anal intercourse, STIs, and HIV among STD clinic clients
Marjan Javanbakht, Ph.D.
University of California, Los Angeles
Los Angeles, CA
$112,193 (2007)

Optimizing HIV Treatment

What they're not telling me: Veterans, trust, and HIV management
Kristin Mattocks, Ph.D.
Yale University
New Haven, CT
$108,480

Impulsivity, drug abuse, and HIV medication adherence: An fMRI study
Christina Meade, Ph.D.
Harvard Medical School–McLean Hospital/
Massachusetts General Hospital
Belmont, MA
$124,000 (2007)

Viral persistence in the MGT of RT-SHIV infected macaques on HAART
Miranda Xhilaga, Ph.D.
Monash University
Melbourne, Australia
$125,000 (2007)

Pursuing HIV Eradication

In vivo modeling of HIV persistence and its eradication
Paul Denton, Ph.D.
University of Texas Southwestern Medical Center at Dallas
Dallas, TX
$125,000

Colorectal responses to HIV-1 and modulation by microbicides
Carolina Herrera, Ph.D.
St George's University of London
London, UK
$125,000 (2007)

HIV mucosal transmission in humanized mice model
Liguo Zhang, Ph.D.
University of North Carolina at Chapel Hill
Chapel Hill, NC
$99,000 (2006)

Molecular mechanisms of the HIV-1 coreceptor CCR5 function
Gabriel Birnane, Ph.D.
Beth Israel Deaconess Medical Center
Boston, MA
$99,000 (2006)

Mechanistic study of retroviral entry and restriction in vitro
Virginie Sandrin, Ph.D.
University of Utah
Salt Lake City, UT
$99,000 (2005)

Designing inducible Pol II systems for RNA interference of HIV-1
Hoshang Unwalla, Ph.D.
Beckman Research Institute of the City of Hope
Duarte, CA
$99,000 (2006)

Mechanism of postentry restriction of HIV-1 by TRIM5alpha
Chisu Song, Ph.D.
Vanderbilt University School of Medicine
Nashville, TN
$99,000 (2005)

The APOBEC3G-Vif interaction as a new HIV therapeutic target
Hendrik Huthoff, Ph.D.
King's College London
London, UK
$99,000 (2005)

Quantitative fMRI of CNS-T ART on HIV brain reservoirs
Beau Ances, M.D., Ph.D.
University of California, San Diego
San Diego, CA
$125,000 (2006)

HIV-1 cell-cell spread in viral dissemination and persistence
Fedde Groot, M.Sc.
The Sir William Dunn School of Pathology
University of Oxford
Oxford, UK
$124,882 (2006)
Virologic correlates of subtype-A HIV transmission
Richard Haaland, Ph.D.
Emory University
Atlanta, GA
$99,000 (2006)

Role of Tat methylation in HIV latency
Sara Pagans, Ph.D.
The J. David Gladstone Institutes
San Francisco, CA
$125,000 (2006)

Macrophage matrix metalloproteinases role in persistence of HIV-1 in CNS
Nicole Webster, Ph.D.
Macfarlane Burnet Institute for Medical Research and Public Health, Ltd.
Melbourne, Victoria, Australia
$125,000 (2006)

HIV reservoir in central memory T cells
Nicolas Chomont, Ph.D.
Université de Montréal, Centre de Recherches du CHUM
Montréal, Québec, Canada
$83,100 (2005)

Identification of novel host factors for HIV replication
Lei Fang, M.D., Ph.D.
Salk Institute for Biological Studies
La Jolla, CA
$99,000 (2005)

Kinetics of HIV reactivation in latently infected T cells
Young Kyeung Kim, Ph.D.
Case Western Reserve University
Cleveland, OH
$99,000 (2005)

Human cellular factors that restrict HIV infection
Susana Valente, Ph.D.
Columbia University in the City of New York
New York, NY

RESEARCH GRANTS

—

Preventing HIV Transmission

—

Neurocognitive factors in the relationship between drug use and risky sex
Sarit Golub, Ph.D.
Research Foundation of the City of New York Flushing, NY
$120,000

HIV prevention efficacy beliefs about male circumcision in South Africa
Joanne Mantell, Ph.D.
HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University
New York, NY
$119,906

Minority stress, social support, and sexual risk in South African MSM
Theodorus Sandfort, Ph.D.
Research Foundation for Mental Hygiene, Inc.
New York, NY
$119,836

HIV conspiracy beliefs among MSM in inner-city slum area of Johannesburg
Waimar Tun, Ph.D.
The Population Council
New York, NY
$119,997

Development of a standard rectal microbicide delivery device
Alex Carballo-Díéguez, Ph.D.
Research Foundation for Mental Hygiene, Inc.
New York, NY
$119,992 (2007)

Colorectal explants to study HIV transmission and microbicides
Charlene Dezzutti, Ph.D.
Magee-Womens Research Institute and Foundation
Pittsburgh, PA
$120,000 (2007)

Epithelial injury and HIV penetration after simulated ejaculation
Craig Hendrix, M.D.
Johns Hopkins University School of Medicine
Baltimore, MD
$120,000 (2007)

How to test: Policy and practice after the CDC recommendations
Lori Leonard, Sc.D.
Johns Hopkins School of Public Health
Baltimore, MD
$120,000 (2007)

Identification of novel host factors for HIV replication
Lei Fang, M.D., Ph.D.
Salk Institute for Biological Studies
La Jolla, CA
$99,000 (2005)

Kinetics of HIV reactivation in latently infected T cells
Young Kyeung Kim, Ph.D.
Case Western Reserve University
Cleveland, OH
$99,000 (2005)

Human cellular factors that restrict HIV infection
Susana Valente, Ph.D.
Columbia University in the City of New York
New York, NY

Mediation effect of network function on HIV risk behavior among Chinese MSM
Hongjie Liu, Ph.D.
School of Medicine, Virginia Commonwealth University
Richmond, VA
$119,988 (2007)

Anal sex practices in high-risk South African women and men
Joanne Mantell, Ph.D.
Research Foundation for Mental Hygiene, Inc.
New York, NY
$119,946 (2007)

Rectal transmission of HIV-1 in a novel mouse model
Roberto Speck, M.D.
Division of Infectious Diseases, Department of Internal Medicine, University Hospital of Zurich
Zurich, Switzerland
$119,822 (2007)

HIV-1 infection of mucosal lymphocytes and tissue explants
Benjamin K. Chen, M.D., Ph.D.
Mount Sinai School of Medicine
New York, NY (2006)
$90,000
Interaction of HIV with the macaque female genital tract
Thomas J. Hope, Ph.D.
Northwestern University
Chicago, IL
$90,000 (2006)

Understanding the properties of transmitted HIV-1 variants
Manish Sagar, M.D.
Brigham and Women’s Hospital/Harvard Medical School
Boston, MA
$90,000 (2006)

Optimizing HIV Treatment

Mistrust of evidence-based medicine affects health outcomes of Latinos
Scott Rhodes, Ph.D.
Wake Forest University Health Sciences
Winston-Salem, NC
$120,000

Recent changes in HIV testing recommendations: Impact on youth at risk
Marya Gwadz, Ph.D.
National Development and Research Institutes USA, Inc.
New York, NY (2007)
$119,598

Impact of PD-1 on the establishment and maintenance of the HIV-1 reservoir
Elias Haddad, Ph.D.
Université de Montréal, Centre de Recherche du CHUM
Montréal, Québec, Canada
$107,668 (2007)

Pursuing HIV Eradication

In vivo virus persistence during suppressive therapy in the RT-SHIV model
Zandrea Ambrose, Ph.D.
University of Pittsburgh
Pittsburgh, PA
$120,000

Autophagy and intracellular HIV in macrophages
Vojo Deretic, Ph.D.
University of New Mexico Health Sciences Center
Albuquerque, NM
$120,000

Animal model for controlled SIV infection
Cristian Apetrei, M.D., Ph.D.
Tulane University
New Orleans, LA
$119,687

HDAC inhibition and chromatin remodeling to disrupt proviral latency
David Margolis, M.D.
University of North Carolina at Chapel Hill
Chapel Hill, NC
$120,000

The impact of stigma on access to HIV treatment and care
Jennifer Sayles, M.D.
University of California, Los Angeles, David Geffen School of Medicine
Los Angeles, CA
$120,000 (2007)

Immune dysfunction and the establishment and maintenance of the HIV-1 reservoir
Sékaly-Robitaille, Ph.D.
Research Foundation for Mental Hygiene, Inc.
New York, NY
$119,684 (2007)

Treatment intensification: Effects on persistent viremia
Sarah Palmer, Ph.D.
Swedish Institute for Infectious Disease Control, Karolinska Institute
Solna, Sweden
$120,000

IL-7 and antigen driven proliferation generate distinct HIV reservoirs
Rafick-Pierre Sékaly, Ph.D.
Université de Montréal, Centre de Recherche du CHUM
Montréal, Québec, Canada
$106,164
Quantification of HIV provirus: Integration and replication competence
Celsi Spina, Ph.D.
Veterans Medical Research Foundation
San Diego, CA
$117,600

Genetic screens for inhibitors of HIV latency
Paul Bieniasz, Ph.D.
Aaron Diamond AIDS Research Center
New York, NY
$120,000 (2006)

HIV controllers: A potential model for HIV eradication
Steven Deeks, M.D.
University of California, San Francisco
San Francisco, CA
$120,000 (2006)

The role of CCR7 ligands and dendritic cells in latent HIV infection
Sharon Lewin, F.R.A.C.P., Ph.D.
Monash University
Melbourne, Victoria, Australia
$120,000 (2006)

Reservoirs of SIV in long term nonprogressors in rhesus macaques
Binhua Ling, M.D., Ph.D.
Tulane National Primate Research Center
Covington, LA
$120,000 (2006)

The GI tract may be a reservoir of ongoing viral replication during HAART
Martin Markowitz, M.D.
Aaron Diamond AIDS Research Center
New York, NY
$120,000 (2006)

Role of lymph node dendritic cells in HIV infection
David McDonald, Ph.D.
Case Western Reserve University
Cleveland, OH
$120,000 (2006)

Identifying the major tissue reservoirs in SIV/SHIV infected macaques
Bapi Pahar, Ph.D.
Tulane National Primate Research Center
Covington, LA
$120,000 (2006)

Effects of valproic acid therapy on gut mucosal HIV reservoirs
Jean-Pierre Routy, M.D.
McGill University Health Centre
Montréal, Québec, Canada
$119,827

RESEARCH AWARDS

Preventing HIV Transmission

Modeling the impact of a rectal microbicide
London School of Hygiene and Tropical Medicine
London, UK
$120,000

Rectal microbicides: Investment and advocacy
AIDS Foundation of Chicago
Chicago, IL
$1,000

Pursuing HIV Eradication

Viral persistence and eradication workshop
Treatment Action Group
New York, NY
$20,000

Role of lymph node dendritic cells in HIV infection
David McDonald, Ph.D.
Case Western Reserve University
Cleveland, OH
$120,000 (2006)

Identifying the major tissue reservoirs in SIV/SHIV infected macaques
Bapi Pahar, Ph.D.
Tulane National Primate Research Center
Covington, LA
$120,000 (2006)

Effects of valproic acid therapy on gut mucosal HIV reservoirs
Jean-Pierre Routy, M.D.
McGill University Health Centre
Montréal, Québec, Canada
$119,827

RESEARCH AWARDS

Preventing HIV Transmission

Modeling the impact of a rectal microbicide
London School of Hygiene and Tropical Medicine
London, UK
$120,000

Rectal microbicides: Investment and advocacy
AIDS Foundation of Chicago
Chicago, IL
$1,000

Pursuing HIV Eradication

Viral persistence and eradication workshop
Treatment Action Group
New York, NY
$20,000

Role of lymph node dendritic cells in HIV infection
David McDonald, Ph.D.
Case Western Reserve University
Cleveland, OH
$120,000 (2006)

Identifying the major tissue reservoirs in SIV/SHIV infected macaques
Bapi Pahar, Ph.D.
Tulane National Primate Research Center
Covington, LA
$120,000 (2006)

Effects of valproic acid therapy on gut mucosal HIV reservoirs
Jean-Pierre Routy, M.D.
McGill University Health Centre
Montréal, Québec, Canada
$119,827
IN DECEMBER 2008, POLICE IN SENEGAL, WEST AFRICA, raided a private house and summarily arrested and detained the nine men inside. They were charged with “establishing an illegal organization” and “committing acts against the order of nature,” hauled off to court, tried, convicted, and sentenced to eight years in jail.

The illegal organization? AIDS Senegal, which provides HIV prevention services to gay men and other men who have sex with men (MSM), and whose leader, Diadj Diouf, was among those arrested. amfAR joined the international community in calling for the men’s release, and while they were subsequently freed after several months of incarceration, the story offers a stark reminder of the challenges and dangers frequently faced by MSM trying to organize grassroots HIV/AIDS programs in many parts of the world.

The reality is that HIV prevention, treatment, and care services for MSM in many parts of the world remain woefully underfunded, inadequate, or—in some countries—nonexistent. Stigma, discrimination, and legal prohibitions against same-sex sexual behavior have fueled the spread of HIV infection among MSM, many of whom remain unaware of their risk and have little or no access to critical services.

amfAR’s MSM Initiative was launched in 2007 in response to the alarmingly high rates of HIV among MSM, who in low- and middle-income countries are on average 19 times more likely to be infected than the general population. The MSM Initiative aims to support and empower grassroots organizations in their efforts to expand HIV prevention, treatment, and care services; build understanding and awareness of HIV epidemics among MSM; and advocate effective HIV-related policies and increased funding to support them.

Supporting Grassroots Action

Since the launch of the MSM Initiative, amfAR has received hundreds of applications for funding, highlighting the urgent need for HIV/AIDS programs serving MSM in the developing world. In fiscal year 2008, amfAR made community awards totaling more than $900,000 to 38 groups in Africa, Asia and the Pacific, the Caribbean, and
Latin America to support access to clinical services and a wide range of HIV prevention, outreach, education, testing, research, and capacity building projects.

Africa — In Cameroon, West Africa, for example, the Initiative is supporting the efforts of the group Alternatives-Cameroun to provide HIV prevention services, free testing, and post-exposure prophylaxis treatment, which can prevent infection if administered shortly after exposure to HIV.

Asia and the Pacific — In Asia, the Initiative is supporting the important work of organizations such as the Blue Diamond Society in Nepal, which is collaborating with the Federation of Sexual and Gender Minorities to provide drop-in testing and hospice services for MSM and transgender people living with HIV.

Caribbean — In the Caribbean, MSM: No Political Agenda, based in Trinidad and Tobago, is producing Free FORUM Project, an online and paper newsletter raising awareness about access to HIV/AIDS/STI treatment, prevention, and advocacy for MSM. And among the ten projects funded in Latin America, La Manta de Mexico is creating a contest-style reality TV show to provide information on HIV and MSM, and has recruited young MSM in Mexico City to act as informal educators.

**Analyzing the Data, Galvanizing the Response**

In support of the international advocacy effort that is necessary to prod governments into action, amfAR is working to document and publicize the extent of the epidemic among MSM and to clearly define the measures required to combat it.

In June, the United Nations General Assembly Special Session (UNGASS) on HIV/AIDS held its 2008 meeting to assess progress on universal access to HIV/AIDS services. The meeting brought together political leaders and country representatives from across the globe. In conjunction with the meeting, amfAR co-hosted a panel of experts to discuss HIV among MSM. The reports from the panelists were uniformly dire, making a clear case for the need to increase HIV-related services and research for MSM.

Globally, sex between men is against the law in 86 countries, and in seven countries it is punishable by death.

At the 2008 International AIDS Conference in Mexico City, amfAR released the world’s first comprehensive report exposing the failure of governments and global health institutions to address the rise of HIV/AIDS among MSM. Titled *MSM, HIV, and the Road to Universal Access—How Far Have We Come?*, it analyzed 128 country reports on HIV/AIDS submitted to the United Nations, finding that nearly half of them failed to provide any data at all on MSM. Despite a unanimous commitment by all UN member countries to monitor HIV among all high-risk groups, the report also found that 91 countries (71 percent) did not have any information on the percentage of MSM being reached by prevention programs.

The report also showed the extent to which criminalization of male-male sex exacerbates the epidemic by driving MSM underground and making them difficult to reach. Globally, sex between men is against the law in 79 countries, and in seven countries it is punishable by death. Significantly, amfAR’s report found that seven of the 10 countries with the highest reported HIV prevalence among MSM were among those that criminalize homosexuality.

In an effort to educate U.S. lawmakers and their staff, in September amfAR presented information on HIV/AIDS among MSM and their lack of access to prevention, care, treatment, and support programs at a Congressional briefing in Washington, D.C. The briefing was held in collaboration with AIDS...
Project Los Angeles, Gay Men’s Health Crisis, and other nongovernmental organizations.

**Moving Forward: Defining the Research Needs**

Shocking gaps in knowledge about MSM and HIV point to the need for more research on the spread of the epidemic among this population, the factors that increase their vulnerability, and the most effective ways to prevent infection.

To address these deficits, amfAR brought together more than 40 experts from around the world for a global research consultation in September 2008. Participants represented a range of disciplines, including epidemiology, biomedicine, social and behavioral science, and human rights. A recently published report of the proceedings details ways to address gaps in knowledge and recommendations for future research.

**Profile**

**VIOLENCE CASTS A PALL ON THE LIVES OF JAMAICAN MSM**

For the past three years, Dr. Robert Carr has worked tirelessly to address the human rights of men who have sex with men (MSM) as volunteer executive director of the Caribbean Vulnerable Communities Coalition. An amfAR MSM Initiative community award has allowed him to build leadership among lesbian, gay, bisexual, and transgender (LGBT) movements in a region known for its virulent anti-gay biases.

“When I discovered how badly people living with HIV/AIDS were treated, without a second thought, I was shocked,” recalls Dr. Carr of his start in AIDS advocacy. “I became an advocate at a time when almost no one was talking about stigma and discrimination in the region and there was a lot of work to be done.”

“The biggest issue now,” said Dr. Carr; “is entrenched homophobia, which is defended loudly in the classroom, in the boardroom, on the streets, in the pulpit, in the media, and in Parliament. To speak up is to risk bodily harm.”

The amfAR community award provided an opportunity to tap into existing networks and begin a dialogue via a consultation and training for MSM community leaders from eight Caribbean countries. “The fact that the conversation is even happening is a major milestone,” said Dr. Carr. “It’s just going to take the time, commitment, and determination... of people who have the strength and courage to differ from the majority, to stay their ground, and to do their best to make a difference.”
All projects listed below were supported by amfAR during the period October 1, 2007, to September 30, 2008. Several organizations have requested anonymity to protect their staff and clients.

**AFRICA**

<table>
<thead>
<tr>
<th>Project</th>
<th>Organization</th>
<th>Location</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Access Project</td>
<td>Alternatives-Cameroun</td>
<td>Douala, Cameroon</td>
<td>$20,000</td>
</tr>
<tr>
<td>Ivoir Plus</td>
<td>International HIV/AIDS Alliance, Brighton, East Sussex, UK</td>
<td>Abidjan, Côte d’Ivoire</td>
<td>$21,000</td>
</tr>
<tr>
<td>Scaling Up MSM HIV/AIDS Intervention Project</td>
<td>Centre for Popular Education and Human Rights</td>
<td>Accra, Ghana</td>
<td>$10,000</td>
</tr>
<tr>
<td>Sexual Minorities and Reproductive Health</td>
<td>Centre for the Development of People</td>
<td>Blantyre, Malawi</td>
<td>$20,000</td>
</tr>
<tr>
<td>Policy and Advocacy</td>
<td>Name withheld by request</td>
<td>Kampala, Uganda</td>
<td>$20,000</td>
</tr>
<tr>
<td>Assessing the HIV/AIDS Burden Among MSM in Abuja, Nigeria</td>
<td>Center for the Right to Health</td>
<td>Lagos, Nigeria</td>
<td>$10,000</td>
</tr>
<tr>
<td>HIV/AIDS Services to MSM Members of a Local Community Group</td>
<td>Hivos, The Hague, Netherlands</td>
<td>Harare, Zimbabwe (name withheld by request)</td>
<td>$10,500</td>
</tr>
</tbody>
</table>

**ASIA-PACIFIC**

<table>
<thead>
<tr>
<th>Project</th>
<th>Organization</th>
<th>Location</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addressing Stigma and Discrimination Against MSM in Bangladesh</td>
<td>Bandhu Social Welfare Society</td>
<td>Dhaka, Bangladesh</td>
<td>$15,000</td>
</tr>
<tr>
<td>Care, Support Program for MSM/TG Living with HIV in Nepal</td>
<td>Blue Diamond Society</td>
<td>Kathmandu, Nepal</td>
<td>$40,000</td>
</tr>
<tr>
<td>Pacific MSM Research Training Program</td>
<td>Pacific Sexual Diversity Network (MSM) – Secretariat, Samoa AIDS Foundation</td>
<td>Apia, Samoa</td>
<td>$40,000</td>
</tr>
<tr>
<td>Civil Rights Support for Members of Kothi Communities in India</td>
<td>UDAAN Trust/National MSM HIV Policy Advocacy and Human Rights Task Force</td>
<td>Mumbai/New Delhi, India</td>
<td>$40,000</td>
</tr>
<tr>
<td>Antidiscrimination and Gender Integration Training for Policy Makers and Implementers</td>
<td>Beijing Gender Health Education Institute</td>
<td>Beijing, China</td>
<td>$15,000</td>
</tr>
<tr>
<td>Heart Talk Support Groups in 12 Cities in China</td>
<td>AIDS Project Los Angeles</td>
<td>Los Angeles, CA</td>
<td>$20,000</td>
</tr>
<tr>
<td>HIV Prevention and Sexual Health Services Among MSM in West Timor</td>
<td>Perkumpulan Keluarga Berencana Indonesia Daerah Nusa Tenggara Timur</td>
<td>Kupang, Indonesia</td>
<td>$15,000</td>
</tr>
<tr>
<td>Forging Stronger Leadership in HIV/AIDS Prevention and Care Among MSM</td>
<td>TLF Sexuality, Health and Rights Educators Collective, Inc.</td>
<td>Makati City, Metro Manila, Philippines</td>
<td>$15,000</td>
</tr>
</tbody>
</table>
### CARIBBEAN

<table>
<thead>
<tr>
<th>Project</th>
<th>Implementor</th>
<th>Location</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bridging Individual Collective Health Action for the MSM Community</td>
<td>United Belize Advocacy Movement</td>
<td>Belize City, Belize</td>
<td>$20,000</td>
</tr>
<tr>
<td>MSM Papiamentu Creole Outreach</td>
<td>Fundashon Orguyo Kòrsou</td>
<td>Willemstad, Curaçao, Netherlands Antilles</td>
<td>$12,990</td>
</tr>
<tr>
<td>MSM and HIV in Haiti</td>
<td>SEROvie</td>
<td>Port-au-Prince, Haiti</td>
<td>$49,888</td>
</tr>
<tr>
<td>Building MSM and GLBT Movements in the Caribbean</td>
<td>Caribbean Vulnerable Communities Coalition</td>
<td>Kingston, Jamaica</td>
<td>$50,000</td>
</tr>
<tr>
<td>Strengthening Risk Reduction Capacity Among MSM in Jamaica</td>
<td>Jamaica AIDS Support for Life</td>
<td>Kingston, Jamaica</td>
<td>$20,000</td>
</tr>
<tr>
<td>From Crisis to Structural Change</td>
<td>Name withheld by request</td>
<td>Kingston, Jamaica</td>
<td>$20,000</td>
</tr>
<tr>
<td>Joint Regional IEC Response to HIV/AIDS in MSM Communities in the Caribbean</td>
<td>MSM: No Political Agenda</td>
<td>Port of Spain, Trinidad and Tobago</td>
<td>$20,000</td>
</tr>
</tbody>
</table>

### GREATER MEKONG SUBREGION

<table>
<thead>
<tr>
<th>Project</th>
<th>Implementor</th>
<th>Location</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transgender Health Issues in Southeast Asia</td>
<td>Name withheld by request</td>
<td>Kuala Lumpur, Malaysia</td>
<td>$20,000</td>
</tr>
<tr>
<td>Intervention, Prevention, Care, and Support</td>
<td>Tides Center, San Francisco, CA</td>
<td>Mandalay, Myanmar (name withheld by request)</td>
<td>$21,000</td>
</tr>
<tr>
<td>Saving People Living With HIV/AIDS Among Men Who Have Sex with Men (MSM)</td>
<td>Tides Center, San Francisco, CA</td>
<td>Yangon, Myanmar (name withheld by request)</td>
<td>$21,000</td>
</tr>
<tr>
<td>Health Services for MSM in Bangkok</td>
<td>Thai Red Cross AIDS Research Centre</td>
<td>Bangkok, Thailand</td>
<td>$20,000</td>
</tr>
<tr>
<td>MSM Sexual Health Clinic at the Thai Red Cross Anonymous Clinic</td>
<td>Thai Red Cross AIDS Research Centre</td>
<td>Bangkok, Thailand</td>
<td>$20,000</td>
</tr>
<tr>
<td>Self-monitoring for Safe Sexual Health (SMS): A Community-Based Study Program</td>
<td>Service Workers in Group (SWING)</td>
<td>Bangkok, Thailand</td>
<td>$20,000</td>
</tr>
</tbody>
</table>
Advocacy on New Regional Authorities in Argentina and Uruguay
Sociedad de Integración Gay Lésbica Argentina
Parque Chacabuco, Argentina
$39,656

Qualitative Research on the Vulnerability of MSM in Santa Cruz to HIV Infection
SEXUALUD
Santa Cruz de la Sierra, Bolivia
$40,000

TRANSfering Technology: Support for National Policies and Local Movements for the Transgender Population in Brazil
Pact Institute/Associação Pact do Brasil Washington, D.C.
$15,000

Characterizing the Vulnerability and Risk of HIV/AIDS and STIs for MSM and Their Sexual Health
ONG Centro Estudio de la Sexualidad Santiago, Chile
$40,000

Coaligay Proposal to Strengthen Public Policies in Guatemala
Organización de Apoyo a una Sexualidad Integral frente al Sida Guatemala City, Guatemala
$15,000

Prevention of HIV Through the Use of an Informative Reality Show
La Manta de México A.C.
Mexico City, Mexico
$15,000

Intervention, Prevention and Testing for MSM in Puerto Vallarta
Vallarta Enfrenta el SIDA, A.C.
Puerto Vallarta, Mexico
$15,000

Increase Safe Sex Practices Amongst Gay, MSM, and Transgender Kuna Indians
Asociación Hombres y Mujeres Nuevos de Panamá
Panama City, Panama
$14,980

Assessment of Social and Health Needs of Perú’s Transgender Population
Instituto de Estudios en Salud, Sexualidad y Desarrollo Humano
Lima, Perú
$14,960

Community-based Trans, Gay, and Bisexual HIV Prevention System
Investigaciones Médicas en Salud
Lima, Perú
$40,000

MSM INITIATIVE AWARDS TO COLLABORATING ORGANIZATIONS

The Collaborative Fund for HIV Treatment Preparedness
Tides Center
San Francisco, CA
$40,000

AIDS-Fondet
Copenhagen, Denmark
$35,000

The Global Forum on MSM and HIV—2008 Steering Committee Meeting
AIDS Project Los Angeles
Los Angeles, CA
$18,850

MAJOR SUPPORT FOR THE MSM INITIATIVE HAS BEEN PROVIDED BY THE FOLLOWING ORGANIZATIONS:

THE ELIZABETH TAYLOR AIDS FOUNDATION
ELTON JOHN AIDS FOUNDATION
GLAAD
POSITIVITY
LEVI STRAUSS FOUNDATION
MAC AIDS FUND
MATHILDE AND ARTHUR B. KRAM FOUNDATION
OPEN SOCIETY INSTITUTE Public Health Program
WITH AN ESTIMATED FIVE MILLION PEOPLE LIVING WITH HIV/AIDS and half a million new infections in 2007, the Asia-Pacific region is second only to sub-Saharan Africa in HIV prevalence. Spanning a vast area from India to Japan to Papua New Guinea, the epidemic in Asia and the Pacific is as diverse and complex as the region itself.

In response to rising rates of infection and the threat of a widespread epidemic, in 2001 amfAR launched a unique initiative aimed at ensuring the safe and effective delivery of HIV/AIDS treatments throughout Asia and the Pacific, and strengthening treatment, care, and management skills among healthcare professionals in the region. TREAT Asia—Therapeutics Research, Education, and AIDS Training in Asia—now includes a network of 20 adult and 22 pediatric hospitals, clinics, and research institutions in 13 countries.

Gathering Essential Data

In an unprecedented regional collaboration, TREAT Asia pioneered the TREAT Asia HIV Observational Database (TAHOD) in 2002. The database now contains anonymous data collected from more than 4,200 treated and untreated patients at 17 clinics in 12 countries across Asia.

The information gathered through TAHOD ultimately could help define treatment standards for Asia and the Pacific—standards that may differ from those in Europe and the U.S. The database seeks in the long term to improve HIV clinical data collection throughout the region, assist in evaluating new HIV treatments, monitor antiretroviral and prophylactic treatment as it relates to demographics and markers of HIV disease stage, monitor toxicity related to antiretroviral therapy, and examine HIV’s natural history, including the relationship between access to antiretroviral therapy and disease progression.

Data generated from TAHOD has formed the basis of numerous scientific journal articles and presentations. In addition to ongoing research, TAHOD investigators developed and circulated a cancer training manual in January 2008 in preparation for a retrospective cancer study. TAHOD investigators also delivered poster presentations concerning their work at international scientific conferences, including the XVII International AIDS Conference.

International Epidemiologic Databases to Evaluate AIDS

TREAT Asia is an integral component of a global data gathering effort known as the International Epidemiologic Databases to Evaluate AIDS (IeDEA), which was established by the U.S. National Institute of Allergy and Infectious Diseases. TREAT Asia manages the Asia-Pacific section of IeDEA and
contributes anonymous data from more than 6,000 patients at 44 clinical centers in Asia, Australia, and the Pacific.

TREAT Asia Studies to Evaluate Resistance
—
Antiretroviral drugs have extended millions of lives around the world, but the long-term success of HIV treatment in resource-limited regions such as Asia and Africa depends on controlling the development of resistance to the limited arsenal of affordable HIV medicines. Working with organizations in the Netherlands, TREAT Asia is conducting a series of complex studies that will allow scientists to understand the emergence and spread of HIV drug resistance.

In 2008, significant progress was made with these studies, which are conducted through a project known as TASER—TREAT Asia Studies to Evaluate Resistance. For a monitoring study, which gauges the emergence of drug-resistant HIV in infected patients, eight clinical centers enrolled more than 850 patients in Hong Kong, Malaysia, the Philippines, and Thailand. For a surveillance study, which evaluates the spread of drug-resistant virus among newly infected patients, four clinical centers enrolled more than 190 patients in Hong Kong, the Philippines, and Thailand.

Underlining TREAT Asia’s role as a leader in HIV drug resistance research, in November 2008 TREAT Asia became one of two private organizations on the World Health Organization’s HIV Resistance Network Steering Committee, which provides guidance for WHO’s global drug resistance surveillance program.

Training New Researchers
—
In order to strengthen the ability of TREAT Asia Network participants to conduct clinical HIV research, TREAT Asia began implementing a research education program in 2008. The first step of the new project, supported by the Australian Agency for International Development, involved the creation of an assessment tool that was used to conduct an initial analysis of research capacity at sites in Jakarta and Bali.

Each year, TREAT Asia also supports and participates in the Bangkok Symposium on HIV Medicine, held this year in January 2008 and organized by HIV-NAT, an AIDS clinic and research center and TREAT Asia Network site based in Bangkok.

TREATING Asia’S CHILDREN
—
Although pediatric HIV/AIDS has been virtually eliminated in the world’s industrialized nations

FEATURE
Caring for Children with HIV: Beyond Medicine

As a pediatrician treating children with HIV, Dr. Nik Khairuludin Nik Yusoff has witnessed the transformation of HIV/AIDS from a death sentence to a largely manageable illness. The life expectancy of his young patients at Malaysia’s Hospital Raja Perempuan Zainab II—a member of TREAT Asia’s pediatric network—has increased thanks to the availability of free antiretroviral therapy (ART), and the number of new infections in children has dropped dramatically over the last decade as a result of government programs to prevent mother-to-child transmission.

But the young patients Dr. Nik sees still face a host of challenges, including poverty, family instability, stigma and discrimination, and resistance to first-line ART. Kota Bharu, where the hospital is located, had the second highest number of new HIV infections in the country in 2007, largely the result of injection drug use. The path of HIV in this area usually starts with infected men who pass the virus on to their wives, who in turn transmit it to their children.

While many of the children and their families face stigma and discrimination, the problem is particularly acute among orphans, many of whom are rejected even by family members. According to Dr. Nik, 50 percent of his HIV-positive patients have lost at least one parent; of these, half have lost both. After more than a decade of caring for children with HIV, Dr. Nik knows that helping them reach adulthood successfully requires more than just medical treatment—they need a commitment by families, communities, and leaders to end stigma and give them the support they need to grow and flourish.
thanks to the widespread availability of drugs that prevent mother-to-child transmission, in Asia approximately 20,000 children are infected with the virus with only a small fraction receiving the treatment they desperately need.

In 2005, more than 138,000 children and adolescents were living with HIV in Asia. By 2006, that number increased 38 percent, to more than 190,000.

TREAT Asia’s Pediatric Network was created in 2005 to form a regional association of pediatric HIV clinicians, researchers, and orphan advocates and to establish a pediatric HIV observational database for epidemiologic research. TREAT Asia’s Pediatric Network now includes 22 sites in eight countries representing more than 6,000 HIV-positive children in Asia.

TAPhOD—the TREAT Asia Pediatric HIV Observational Database—began collecting data in March 2008 from the network’s pediatric clinical centers. By October, TAPhOD included data from 2,200 pediatric patients at 12 clinics in Cambodia, India, Indonesia, Malaysia, and Thailand. One of the linepins of TAPhOD is a customized electronic data collection program that can help sites with clinical management while functioning as a research tool. Providing this database and training staff to use it represents meaningful capacity building, a key objective to which the pediatric program is firmly committed.

PROFILE
FINDING A BRIGHT FUTURE IN VIETNAM

Bui Thi Bien is a treatment literacy educator in Vietnam and the leader of Bright Futures Thai Binh, a support group for people living with HIV/AIDS. Her work is supported by a grant from TREAT Asia.

“I was born in a poor village in Kien Xuong district of Thai Binh province and I got married when I was 19 years old. When I was six months pregnant, I got a blood test and a month later I received an HIV-positive result. I was so shocked I nearly became unconscious.

“My husband started to get sick and I had to take care of him. To protect the baby, I went to the local health station to the PMTCT [prevention of mother-to-child transmission] program. After two months of sickness without any treatment, my husband passed away, and I delivered my third child 10 days after his death.

“After a while, I began to learn more about HIV and I started to speak out publicly about my status. Things began to change and I thought of establishing a support group in our village. Our monthly meetings helped members monitor and manage their health, and group activities attracted many people seeking spiritual and physical care and support.

“In a small way I have participated in breaking the barriers of stigma and discrimination and have helped others living with HIV/AIDS feel confident about disclosing their status and getting treated. Now my support group is big and my children are growing up. Thinking back to five years before I was first diagnosed, I could never have imagined I would have such a bright future.”

A COMMUNITY-LEVEL RESPONSE

A founding principle of TREAT Asia is that effective delivery of antiretroviral treatment across Asia requires the active participation of civil society, including people living with HIV/AIDS. Through a wide variety of projects, TREAT Asia seeks to strengthen the understanding of treatment among Asia’s most affected communities.

Treatment Education and Support

While almost one-third of adult HIV infections in Asia occur among women, few prevention, treatment, or care programs are tailored specifically to their needs. To address this deficit, TREAT Asia supports a variety of projects supporting the varied needs of HIV-positive women. In Cambodia, where TREAT Asia has been working closely with the Cambodian Community of Women Living with HIV (CCW), monthly treatment literacy education workshops have been organized, and members of CCW are now being trained.
to train other women. With TREAT Asia’s support, in 2008 CCW also formed Cambodia’s first women’s treatment access working group.

Treatment literacy trainings also took place during 2008 for HIV-positive women in Vietnam (in Thai Binh and Ninh Binh provinces) and in Indonesia, and TREAT Asia funded the establishment of women’s PLHWA support groups in Cambodia and Vietnam. Similar programs for both genders were held in Vietnam and Papua New Guinea.

AIDS Care in China
—
TREAT Asia continues to work closely in China with a community-based treatment support organization called AIDS Care China (see sidebar) In 2008, TREAT Asia partnered with AIDS Care China to open two new programs supporting more than 1,000 people on ARV treatment and bringing the total number of AIDS Care China’s centers to four.

The effectiveness of the innovative AIDS Care China model, which involves providing HIV support services in close collaboration with medical clinics, was demonstrated by a 2008 study that looked at the number of HIV patients who remained consistently in treatment, as opposed to those who left care. The study found that between July 2007 and

March 2008, the average lost-to-follow-up rate dropped dramatically from 29.3 percent to less than 1 percent.

Linking the Clinic to the Community
—
TREAT Asia convened a think tank in September 2008 to identify strategies for linking PLHWA to the network’s clinical care, treatment, and research activities. Participants included HIV clinical providers and PLHWA representatives from around Asia. Attendees confirmed the need for a pilot program organized by TREAT Asia to connect existing clinical sites to community groups, and

“Extensive, scientific evidence for the effectiveness of opiate substitution therapy and needle exchange therapy have been done over the last 20 years...Yet, out of the 185 countries that have injecting drug use, only 77 countries have implemented needle exchange. Even fewer countries have opiate substitution treatment. What is stopping us? In most instances, evidence based treatment is put aside for what I call non-evidence based treatment, based on incarceration and punitive actions.

“So what is the way forward? Obviously, we need to stop arguing about the merits of harm reduction and just do it.”

TAKING A STAND
MAKING THE CASE FOR HARM REDUCTION: DR. ADEEBA KAMARULZAMAN

Dr. Adeeba Kamarulzaman, chair of the TREAT Asia Steering Committee, urged countries to implement harm reduction measures as part of the fight against HIV/AIDS in her plenary address at the XVII International AIDS Conference in Mexico City, August 2008. “According to recent estimates, there are approximately 11 million injecting drug users around the world, of whom more than 3.3 million are infected with HIV. We know that outside sub-Saharan Africa, 30 percent of HIV infections are due to injecting drug use.

“Extensive, scientific evidence for the effectiveness of opiate substitution therapy and needle exchange therapy have been done over the last 20 years...Yet, out of the 185 countries that have injecting drug use, only 77 countries have implemented needle exchange. Even fewer countries have opiate substitution treatment. What is stopping us? In most instances, evidence based treatment is put aside for what I call non-evidence based treatment, based on incarceration and punitive actions.

“So what is the way forward? Obviously, we need to stop arguing about the merits of harm reduction and just do it.”
specifically to encourage community involvement within local sites and potentially at the network level.

The Purple Sky Network

In recent years, scattered studies in the Asia-Pacific region have begun to reveal a surging HIV epidemic among men who have sex with men (MSM), but few programs exist to curb the spread of infection and to provide essential treatment, care, and support services. For several years, TREAT Asia has served as regional coordination secretariat for the Purple Sky Network, which works with more than 80 MSM organizations to address the rise of HIV in the Greater Mekong Sub-region. Purple Sky organized a workshop in September 2008 to provide in-depth education and information sharing among members of government working groups from China, Vietnam, and Thailand. In December, the network organized the first regional behavior change communication training in Cambodia.

Representatives of the Purple Sky Network also presented two posters at the XVII International AIDS Conference, one examining their experience as part of a regional partnership fighting the epidemic among MSM and the second reviewing an MSM peer reference manual they had created.

Regional and Global Leadership

TREAT Asia works closely with local clinics throughout Asia, but the program is also recognized as a strong regional and global leader. In 2008, TREAT Asia participated at major scientific conferences including the XVII International AIDS Conference in Mexico City. Activities included a presentation at a major pre-conference event sharing best practices from Asia that have helped to strengthen MSM advocacy; a report on the progress of TASER; two poster presentations on TAHOD research; a third poster on standardizing HIV genotypic resistance testing; and two additional posters from the Purple Sky Network.
2008 TREAT ASIA AWARDS, SUBAWARDS, AND TECHNICAL SUPPORT CONTRACTS

All projects listed below were supported by amfAR during the period October 1, 2007, to September 30, 2008. Grants funded during fiscal year 2008 but awarded in previous years are shown with the year of the award in parentheses.

ASIA PACIFIC HIV OBSERVATIONAL DATABASE (APHOD)

—
Matthew G. Law, Ph.D.
National Centre in HIV Epidemiology and Clinical Research
University of New South Wales
Darlinghurst, Australia
$258,340 (Year 3 Subaward)
$16,137 (Year 2 Supplemental Funding)
$238,069 (2007–Year 2 Subaward)

TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD)

—
Yi-Ming Chen, M.D., Sc.D.
National Yang-Ming University
Taipei, China
$170,000 (Year 3 Subaward)
$2,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Jun Yong Choi, M.D., Ph.D.
Yonsei University College of Medicine
Seoul, South Korea
$170,000 (Year 3 Subaward)
$2,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Rossana Ditangco, M.D.
Research Institute for Tropical Medicine
Muntinlupa City, Philippines
$15,000 (2007–Year 2 Subaward)
$2,000 (Cancer Study Subaward)

Rossana Ditangco, M.D.
Asian Foundation for Tropical Medicine, Inc.
Muntinlupa City, Philippines
$170,000 (Year 3 Subaward)

Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P.
University of Malaya
Kuala Lumpur, Malaysia
$18,000 (Year 3 Subaward)
$2,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Nagalingeswaran Kumasamy, M.D., M.B.B.S., Ph.D.
YRG Centre for AIDS Research and Education, VHS
Chennai, India
$25,000 (Year 3 Subaward)
$8,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Christopher Lee, M.B.B.S., M.R.C.P.
Sungai Buloh Hospital
Sungai Buloh, Malaysia
$20,000 (Year 3 Subaward)
$2,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Patrick Li, M.B.B.S.
Queen Elizabeth Hospital
Hong Kong, China
$23,000 (Year 3 Subaward)
$2,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Poh Lian Lim, M.D., M.P.H.
Tan Tock Seng Hospital
Singapore
$19,000 (Year 3 Subaward)
$2,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Tuti Parwati Merati, M.D.
Udayana University School of Medicine
Denpasar, Indonesia
$17,000 (Year 3 Subaward)

Shinichi Oka, M.D.
International Medical Center of Japan
Shinjuku-ku, Japan
$15,000 (Year 3 Subaward)
$15,000 (2007–Year 2 Subaward)

Praphan Phanupak, M.D., Ph.D.
HIV-NAT/Thai Red Cross Research Center
Bangkok, Thailand
$170,000 (Year 3 Subaward)
$2,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Sanjay Pujari, M.D.
Institute of Infectious Diseases
Pune, India
$21,000 (Year 3 Subaward)
$2,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)

Vonthanak Saphonn, M.D., Ph.D.
National Center for HIV/AIDS, Dermatology, and STDs
Cambodia National Institute of Public Health
Phnom Penh, Cambodia
$17,000 (Year 3 Subaward)
$4,000 (Cancer Study Subaward)
$15,000 (2007–Year 2 Subaward)
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City, Country</th>
<th>Amount 1</th>
<th>Amount 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thira Sirisanthana, M.D.</td>
<td>Chiang Mai University</td>
<td>Chiang Mai, Thailand</td>
<td>$15,000</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$15,000 (2007–Year 2 Subaward)</td>
</tr>
<tr>
<td>Fujie Zhang, M.D.</td>
<td></td>
<td>Beijing, China</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Somnuek Sungkanupraph, M.D.</td>
<td>Bangkok, Thailand</td>
<td>$20,000</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td>Ramathibodi Hospital, Mahidol University</td>
<td></td>
<td>$4,000</td>
<td>(Cancer Study Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$15,000 (2007–Year 2 Subaward)</td>
</tr>
</tbody>
</table>

**AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City, Country</th>
<th>Amount 1</th>
<th>Amount 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debra Allen, M.B.Ch.B., Dip. Med.</td>
<td>Northern Sydney Central Coast Area Health Services, Holden Street Clinic</td>
<td>Gosford, Australia</td>
<td>$2,925</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$1,725 (Year 2 Subaward)</td>
</tr>
<tr>
<td>William Donohue, M.B.B.S.</td>
<td>University of Adelaide, Care and Prevention Program</td>
<td>Adelaide, Australia</td>
<td>$2,250</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$2,175 (2007–Year 2 Subaward)</td>
</tr>
<tr>
<td>Mark Bloch, M.D.</td>
<td>Holdsworth House Medical Practice</td>
<td>Sydney, Australia</td>
<td>$7,500</td>
<td>(Year 3 Contract)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$7,500 (Year 2 Contract)</td>
</tr>
<tr>
<td>Dr. Anuja Kulatunga</td>
<td>Northern Territory Department of Health Casuarina, Australia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$1,575</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$975 (2007–Year 2 Subaward)</td>
</tr>
<tr>
<td>Dr. Eva Jackson</td>
<td>Blue Mountains Sexual Health and HIV Clinic</td>
<td>Katoomba, Australia</td>
<td>$3,675</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$1,725 (2007–Year 2 Subaward)</td>
</tr>
<tr>
<td>John Chuah, M.B.B.S., B.Sc.</td>
<td>Gold Coast Health Service District</td>
<td>Miami, Australia</td>
<td>$7,500</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$7,500 (2007–Year 2 Subaward)</td>
</tr>
<tr>
<td>Jennifer Hoy, M.B.B.S.</td>
<td>Victorian HIV Service, Alfred Hospital</td>
<td>Melbourne, Australia</td>
<td>$7,500</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$7,500 (2007–Year 2 Subaward)</td>
</tr>
<tr>
<td>Mun Tong Liang, F.A.Ch.S.H.M.</td>
<td>Nepean Sexual Health Clinic</td>
<td>Sydney, Australia</td>
<td>$2,250</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$1,350 (2007–Year 2 Subaward)</td>
</tr>
<tr>
<td>Richard Moore, M.B.B.S.</td>
<td>Carlton Clinic</td>
<td>Carlton, Australia</td>
<td>$7,500</td>
<td>(Year 3 Contract)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$7,500 (2007 Subaward)</td>
</tr>
<tr>
<td>David Nolan, Ph.D.</td>
<td>Royal Perth Hospital</td>
<td>Perth, Australia</td>
<td>$7,500</td>
<td>(Year 3 Subaward)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$7,500 (2007–Year 2 Subaward)</td>
</tr>
</tbody>
</table>
Catherine O’Connor, M.B.B.S., F.A.Ch.S.H.M.  
Livingstone Road Sexual Health Centre  
Marrickville, Australia  
$2,925 (Year 3 Subaward)  
$750 (2007–Year 2 Subaward)  

Gladstone Road Medical Centre  
Highgate Hill, Australia  
$7,500 (Year 3 Contract)  
$3,000 (Year 2 Contract)  

Dr. Tim Read  
Melbourne Sexual Health Centre  
Carlton, Australia  
$7,500 (Year 3 Subaward)  
$6,300 (2007–Year 2 Subaward)  

Dr. David Smith  
Sexual Health and AIDS Services  
Lismore, Australia  
$7,500 (Year 3 Subaward)  
$5,775 (2007–Year 2 Subaward)  

Matthew G. Law, Ph.D.  
National Centre in HIV Epidemiology and Clinical Research  
University of New South Wales  
Darlinghurst, Australia  
$173,039 (Year 2 Subaward)  
$172,800 (2007–Year 1 Subaward)  

Matthias R. U. Schirmer, M.D.  
Gとなっている。
TREAT ASIA QUALITY ASSURANCE SCHEME (TAQAS)

Matthew G. Law, Ph.D.
National Centre in HIV Epidemiology and Clinical Research
University of New South Wales
Darlinghurst, Australia
$204,933 (Year 3 Subaward)
$161,468 (2007–Year 2 Subaward)

TREAT ASIA STUDIES TO EVALUATE RESISTANCE (TASER)

Rossana Ditangco, M.D.
Research Institute for Tropical Medicine
Muntinlupa City, Philippines
$66,000 (Year 2 Subaward)

Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P.
University of Malaya Clinical Investigation Center
Kuala Lumpur, Malaysia
$2,040 (Drug Resistance Training)
$66,000 (Year 2 Subaward)
$50,000 (2007–Year 1 Subaward)

Nagalingeswaran Kumarasamy, M.D., M.B.B.S., Ph.D.
YRG Centre for AIDS Research and Education, VHS
Chennai, India
$66,000 (Year 2 Subaward)
$50,000 (2007–Year 1 Subaward)

Matthew G. Law, Ph.D.
National Centre in HIV Epidemiology and Clinical Research
University of New South Wales
Darlinghurst, Australia
$165,530 (Year 3 Subaward)
$190,178 (2007–Year 2 Subaward)

Christopher Lee, M.B.B.S., M.R.C.P.
Sungai Buloh Hospital
Sungai Buloh, Malaysia
$66,000 (Year 2 Subaward)
$50,000 (2007–Year 1 Subaward)

Tuti Parwati Merati, M.D.
Udayana University School of Medicine
Denpasar, Indonesia
$66,000 (Year 2 Subaward)
$6,200 (Drug Resistance Training Subaward)

Praphan Phanuphak, M.D., Ph.D.
HIV-NAT/Thai Red Cross Research Center
Bangkok, Thailand
$66,000 (Year 2 Subaward)
$50,000 (2007–Year 1 Subaward)

Sanjay Pujari, M.D.
Institute of Infectious Diseases
Pune, India
$66,000 (Year 2 Subaward)
$50,000 (2007–Year 1 Subaward)

Thira Sirisanthana, M.D.
Chiang Mai University
Chiang Mai, Thailand
$66,000 (Year 2 Subaward)
$6,863 (Technical Assistance Subaward)

Somnuek Sungkanuparp, M.D.
Ramathibodi Hospital, Mahidol University
Bangkok, Thailand
$66,000 (Year 2 Subaward)

TREAT ASIA AWARDS

HIV/AIDS Treatment Literacy Training
Tao Cai
AIDS Care China
Nanning, China
$74,540

Cambodian Treatment Literacy Project
Pharozin Pheng
Cambodian People Living with HIV/AIDS Network
Phnom Penh, Cambodia
$26,624

Women and Treatment Literacy Training Support Project
T.R.P. Gustav Simanjuntak
PITA Foundation
Jakarta Pusat, Indonesia
$27,530

HIV-Positive Women Treatment Literacy Trainings
Diu Nguyen Thi
World Concern Vietnam
Hanoi, Vietnam
$18,710

The Treatment Education and Literacy Project
Ong Van Tung
The Center for Public Health and Community Development
Hanoi, Vietnam
$17,954
ADVOCACY & OUTREACH

RESEARCH ALONE CANNOT HALT AIDS. Progress against the epidemic is dependent on the continual communication, distribution, and application of new knowledge about HIV gained from scientific studies.

One of amfAR’s strengths is its reputation as an authoritative source of unbiased, evidence-based information on HIV/AIDS. This is particularly important for the public, healthcare professionals, the media, the HIV/AIDS community, and for those who are ultimately responsible for putting research into policy—lawmakers and health officials.

amfAR’s public policy priorities include the development and implementation of a national AIDS strategy; increased federal funding for HIV/AIDS research, including vaccines, chemoprevention, microbicides, and behavioral studies; removal of the ban on federal funding for syringe exchange programs; expansion of access to care and treatment; and protection of the civil rights of all people affected by HIV/AIDS.

In 2008, the Foundation made its voice heard on these and other pressing issues such as women and HIV, the epidemic in U.S. correctional facilities, eradicating stigma, and the disproportionate impact of HIV on communities of color.

BEARING THE BRUNT: WOMEN AND HIV

Women now make up half of all people living with the virus worldwide and bear much of the burden of caring for infected family members. amfAR is a vocal proponent of expanding HIV/AIDS services for women in the U.S. and around the world. In March 2008, the Foundation held a briefing with leading experts at the National Press Club in Washington, D.C. moderated by amfAR’s senior policy and medical advisor, Susan Blumenthal, M.D., to release the findings of an amfAR-sponsored survey conducted by Harris Interactive. The survey revealed strikingly high levels of stigma against HIV-positive women in the U.S. More than a quarter of those surveyed reported that they would be uncomfortable being close friends with an HIV-positive woman.

"Violence against women is both a cause and a consequence of HIV infection."
— Women and HIV/AIDS, amfAR issue brief 2008

In a fact sheet produced in conjunction with the briefing, amfAR detailed the factors that make women especially vulnerable to HIV infection and issued policy recommendations for improving prevention, treatment, and care for women and girls in the U.S. and around the world. The fact sheet was distributed to members of Congress and their staff, as well as to participants at the Women and HIV International Clinical Conference co-sponsored by amfAR and held in Dallas in April 2008.
AN EPIDEMIC BEHIND BARS

The U.S. incarcerates more people than any other country in the world, with one in 100 adults held in prisons and jails at the end of 2006. Since HIV/AIDS prevalence among prisoners is more than three times greater than that of the general U.S. population, and more than 90 percent of inmates eventually return to their communities, the spread of HIV within correctional facilities has implications that extend far beyond prison walls, particularly in communities of color.

"If you want to address HIV in your community, and if you are not looking at what’s going on in the correctional population, you are missing one in four of people with HIV."

— Dr. Josiah Rich, professor of medicine and community health at Brown University, at amfAR’s April 2008 Congressional briefing

In April 2008, amfAR organized a Congressional briefing that brought experts together to discuss and develop strategies for curbing the disproportionately high rates of HIV/AIDS in correctional facilities. For the briefing, amfAR published an issue brief analyzing the factors that contribute to high rates of infection in prison and released policy recommendations regarding routine testing, comprehensive HIV education programs, condom distribution, harm reduction, treatment and care during and after incarceration, and measures to reduce stigma and discrimination.

PROVEN PREVENTION: HARM REDUCTION

Injection drug use is believed to be responsible for 16 percent of new HIV infections in the U.S. and 10 percent of new HIV infections worldwide. In Eastern Europe and parts of Asia, injection drug users (IDUs) account for a high proportion of people living with HIV. Transmission among IDUs occurs not only through contaminated injection equipment but also through sexual transmission and from mothers to their children. amfAR has long been a leading advocate of syringe exchange as a method of preventing the transmission of HIV among IDUs and their partners and families. Since the 1980s, syringe exchange programs in conjunction with other harm reduction strategies have led to an 80 percent decrease in new HIV infections among IDUs.

The principal obstacle to widespread uptake of syringe exchange is a longstanding Congressional ban on federal funding for such programs. Providing national leadership on this issue, amfAR is a staunch and vocal proponent of the ban’s repeal. In November 2007, the Foundation released a revised fact sheet on the subject, which summarized the overwhelming evidence that syringe exchange is effective at reducing the spread of HIV without increasing illegal drug use.

In addition, through a contract with the New York State Department of Health, amfAR administers the distribution of syringe exchange supplies to the state’s 17 authorized syringe exchange programs, which have served more than 130,000 people. In 2008 the Foundation distributed more than 2.1 million syringes and 2.3 million condoms, along with more than 1,000 cases of rapid HIV test kits and 1,500 overdose prevention kits.

PREVENTION IS THE CURE

On World AIDS Day, December 1, 2007, amfAR launched a transatlantic public service advertising campaign that appeared on subways and buses in New York and London. On a black background, red, gray, and white lettering announced a stark truth: “We’re Forgetting AIDS.” The ads, which were designed and donated by Kenneth Cole Productions,

FEATURE
SYRINGE EXCHANGE TRANSFORMS LIVES IN HARLEM

Two trailers sit in the shadow of the commuter train tracks, which rise above New York City’s East Harlem. On a sunny morning, most of the people who stop at this mobile syringe exchange site stay only minutes, to exchange used syringes for clean ones or to pick up safe injecting supplies, condoms, and literature. These brief interactions are part of a much larger trend: the dramatic reduction of HIV infections among IDUs in New York, as well as lasting, visible change within communities like East Harlem. amfAR has played an integral role in syringe exchange in New York since before it was legal, funding early studies showing the benefits of harm reduction, and providing seed funding for the first legal syringe exchange programs in New York City. Since 1992, amfAR has administered the distribution of supplies to all the state’s programs. In many states, the debate about syringe exchange rages on, but in New York, the practice has been shown to be an unqualified success.

Syringe Exchange: The Facts
- The proportion of IDUs with HIV in New York City dropped from 50 percent in 1990–1992 to 15 percent in 1999–2002.
- During the same period, the number of syringes exchanged per year in the city increased from 250,000 to 3 million.
- The projected lifetime cost of treating just one person with HIV in the U.S. is $400,000–$600,000.
- The highest-funded syringe exchange program in New York State receives less than $300,000 per year, and pays for itself by PREVENTING.
promoted the theme “Prevention Is the Cure.” amfAR Chairman of the Board
Kenneth Cole appeared on Larry King Live and CNBC’s The Big Idea to
announce the launch of the campaign and discuss amfAR’s work.

amfAR also publicly championed
evidence-based prevention and sex
education on Capitol Hill. In April 2008,
CEO Kevin Robert Frost submitted
written testimony to Congress on the
ineffectiveness of abstinence-only
programs. In his testimony, Frost urged
officials to promote comprehensive sex
education programs that include
information about condom use,
contraception, and sexually transmitted
infections, arguing that, “To do otherwise
ignores the rights and realities of young
people and denies them the knowledge
needed to safeguard their health.”

Educating Healthcare Providers

— amfAR is one of only a handful of AIDS
organizations authorized by the
Accreditation Council for Continuing
Medical Education (ACMME) to provide
HIV education credits through its
professional education courses for
physicians, nurses, nurse practitioners,
physician assistants, and other healthcare
professionals. In addition to providing
continuing medical education (CME)
credits to healthcare professionals at the
Women and HIV International Clinical
Conference in Dallas (see above), amfAR
co-sponsored a CME dinner meeting for
healthcare professionals who provide
care for HIV-positive pregnant women.

In March and April 2008, the
Foundation co-sponsored one-day
conferences in Olympia, Washington, and
Salem, Oregon, for clinicians who provide
treatment for HIV patients in
correctional facilities. And in June 2008,
amfAR was the co-sponsor of a one-day
program in Houston that provided
information on medical management,
treatment, and care of HIV patients.

In the Spotlight

— As a respected voice on HIV/AIDS,
amfAR is frequently called upon by the
media to provide insights and analysis on
research developments and other aspects
of the epidemic. amfAR staff and
researchers supported by the Foundation
were featured in diverse media outlets
throughout 2008, including the
Washington Post, Washington Times,
Financial Times, Time, Huffington Post,
CBS Evening, BBC Radio, and National
Public Radio.

amfAR’s educational and advocacy
efforts are greatly enhanced by the
committed support of celebrities from
the fields of music, film, fashion, and art,
who lend their voices and donate their
time, talents, and resources to help
sustain the Foundation’s mission. In
2008, these supporters included Sharon
Stone, amfAR’s Global Fundraising
Chairman, amfAR Board Member
Natasha Richardson, and amfAR
Ambassadors Milla Jovovich and
Michelle Yeoh, as well as Kim Cattrall,
Cheyenne Jackson, Madonna, Stanley
Tucci, Harvey Weinstein, and many
others. In an era of widespread
complacency on HIV/AIDS, their
generous assistance in promoting the
need for AIDS research, prevention, and
education and is as important as ever.

2008 Public Policy Awards

All projects listed below were supported by amfAR during the period October 1, 2007, to September 30, 2008.

The Evolving Ethics and Politics for HIV Testing
Ronald Bayer, Ph.D.
Columbia University, Joseph L. Mailman
School of Public Health
New York, NY
$66,000

7th National Harm Reduction Conference
Paula Santiago
Harm Reduction Coalition
New York, NY
$10,000

HIV/AIDS in the 21st Century: Charting
New Research Frontiers
Mary Woolley
Research!America
Alexandria, VA
$100,000

CHAMP Workshop, Research Advocacy for HIV Prevention (Boston)
Julie Davids
Community HIV/AIDS Mobilization Project
Providence, RI
$3,000

CHAMP Workshop, Research Advocacy for HIV Prevention (Atlanta)
Julie Davids
Community HIV/AIDS Mobilization Project
Providence, RI
$3,000

Women and HIV International Clinical Conference
Laura Armas-Kolostroubism, M.D.
Parkland Foundation
Dallas, TX
$5,000
$10,000 (supplemental funding)

2008 United States Conference on AIDS
Paul Kawata
National Minority AIDS Council
Washington, DC.
$5,000
amfAR’s accomplishments in the fight against AIDS would not be possible without generous support from individual and institutional donors.

**INDIVIDUAL GIVING**

Generous support from individual donors form the backbone of amfAR’s efforts to control and eradicate HIV/AIDS. The following individuals and families contributed or raised $1000 or more between October 1, 2007 and September 30, 2008. amfAR acknowledges with gratitude the thousands of other donors whose generous contributions, tribute gifts, and benefit event ticket purchases have helped bring us closer to our goal of a world without AIDS.

### $25,000+

- Hussein Adam Ali
- Ahmed Al Hamad
- Arlen and Michele Andelson
- Akash O. Aurora
- Gabriel and Ann Barbier-Mueller
- Angela Barrett
- David C. Bohnett and Tom Gregory
- Hermann Bühlecker
- Benny Caiola, Jr.
- Jonathan S. Canno
- Donald A. Capoccia
- David A. Carrillo and Lisa Sardegna
- R. Martin R. Chavez, Ph.D.
- Gerard Cohen
- Kenneth and Maria Cole
- James P. Collins and Lindsey A. Siegrist
- David C. Copley
- Kenneth and Patricia Crews
- Umar Dzhabrailov
- Amir and Maria Ecker
- Walter and Laura Elcock
- Ottavio and Roberta Fabbri
- Ian Fairservice
- Vernon E. Faulconer
- Milutin Gatsby
- Tommy Hilfiger
- Lee and Ann Hobson
- Marguerite S. Hoffman
- Alexander and Jane Jackson
- Anita M. Jaffe
- Salar Kamangar
- Bob and Susan Kaminski
- Ryan Kavanaugh
- Alfiya Kuanyshova
- Laurence H. Lebowitz and Naomi Aberly
- Michel Litvak
- Alexandra Melnichenko
- Susan B. Montgomery
- Jerry Murdock, Jr.
- George Z. G. Mushahwar and Rula Madanat
- James and Shelley Musselman
- A. Jerrold Perenchio
- H. Ross and Sarah Perot
- Patricia A. Quick
- Howard and Cindy Rachofsky
- Corrado Riccio
- William and Catherine M. Rose
- Rusty and Deedie Rose
- Edward Rose, III and Evelyn P. Rose
- William and Rozanne Rosenthal
- Dimitri and Elana Rybolovlev
- Kenan Seginer
- Natalia Selivanova
- Khosiyat Shokirova
- Roderick B. Thomson
- Camilla Towers
- Edward Walson
- Gary and Nina Wexler
- Michael and Sharon Young
- Anonymous (2)

### $10,000 - $24,999

- Basel Al Kasem
- Louis Andy
- Christian Angermayer
- Arturo Artom
- Steven Becker
- Peter D. Beitsch, M.D.
- Francesco and Marisa Bellini
- Nicholas Berggruen
- Jaka Bizilj
- Christina Bloom
- Stephen B. Brady
- Julie Candice
- Donald J. Carty
- Vikram Chatwal and Priya Sachdev
- Jiesa Chiminzazzo
- James H. Coleman
- Rex Cumming
- Maurice Dabbah and Victoria Silvestedt
- Anthony J. De Nicola
- Jeff and Shannon Estes
- Joseph S. Fichera
- Eric K. Fischl
- Jack P. Freinhar, M.D.
- Giancarlo Giammetti
- Kenny Goss and George Michael
- Daniella Helayel
- Michelle Herbert
- Sandra Howarth
- F. Curt Kirschner, Jr. and Nicholas Augustinos
- Ella Krasner
- Peter and Lisa Kraus
- Viktor Kravovitski
- Jeff and Terry Kurz
- Brian and Rachel Ladin
- William E. Little, Jr. and Helen Little
- Hall and Letty McAdams
- Shelia W. McAdams
- Megan and Casey McManemin
- Richard H. Metzner and Mark Sapitsky
- Julia Moore
- Joseph M. Nichol
- James Palmer
- Lucilo A. Pena
- Elizabeth Peyton
- Alden Pinnell
- Justin and Natalia Portman
- Carol A. Prugh
- Nicolas Rachline
- Eve Reid
- Bruce and Avis Richards
- Vincent A. Roberti
- William Roberti
- Daniel and Elizabeth Routman
- John and Lisa Runyon
- Ahmad Sharaf
- Jim and Jan Showers
- Kenneth and Marissa Starr
- Tom and Blake Stephenson
- James C. Sullivan
$1,000 - $9,999

David Acker
Warren and Jan Adelson
Jamiel Akhtar
Frank Aldridge, III and Brooke S. Aldridge
Robert Allday
Jay L. Althouse and Sally Kay Albrecht
Will Ameringer
Paul Arata and Scott Foster
Gary Armstrong
Michael Artura
Richard K. Baird, Jr.
Ray A. Balestri
Robert E. Ballew
Merrill Barlow, IV
Daniel Barney
Brooke D. Barrett
Scott Bass and Dominic F. Chiarello
Bruce W. Bastian
Alvin H. Baum, Jr.
Leo and Naomi Beck
George W. Beddingfield
Al and Pamela Bendich
Gary D. Bennett
Robert Bennett
Robin Bergen
Adam and Karen Berkowitz
Anthony M. Berson, M.D.
Gerard A. Bertolino
Ken and Gina Bettis
Allen D. Black and Randy Apgar
Allen L. Blaich
Robert L. Block, M.D. and Christine Cornachio-Block, M.D.
Susan Blumenthal, M.D.
Edward Bockius
Brian R. Bolke
Carol Bonnie
Andy Boose and Bennah Serfaty
Burton Borman
James S. Bowler
Tabitha M. Bowling
Patrick Bradbury
David K. Bradley
Paul and Maxine Bradley
Philip D. Brandt
Zev and Mayling Braun
David W. Briggs
Faye C. Briggs
Barbara J. Brockardt
Peter and Lael Brodsky
Arthur L. Brown
Bradley O. Brown
Constance A. Brown
David S. Brown
Lloyd R. Brown
James W. Budke, M.D. and Marlene Humn
Gunter Bueschl
Michael Bull
Leland Burk and Thomas Feulner
Laurie Burns
Paul D. Cadwallader
Renee Cafiero
Walter M. Cain
Vincent Calcagno
Stephen P. Carlino and Dennis R. Fee
Robert Carrozza
Zeno Castro
Gabriel Catone
Michael J. Cesario
Richard L. Chadakoff
Helen D. Chatman
James and Victoria Chang
Tracy Chapman
Nick Chavez
Martin Samuel Checov
Diego Cisneros
Robert W. Clausen, M.D.
Jeffrey A. Cole
Eric Coleman
Kristen B. Coleman
Maurice P. Collins, Jr.
Robert Colombo
Michael and Linda Connelly
Albert B. Connor
Sarah Conrad
Alfred and Alvina Contarino
Andrew and Wendi Cookler
Michael Corman
George B. Cotkin
Patrick P. Coyne
Aparna M. Crosnoe
Gregg R. Crumley
J. Patrick Curry
Thomas B. Curtis
Richard R. D’Alessandro
L. Scott Danchik
Lawrence J. Danicic
Don and Barbara Daseke
John and Arlene Dayton
Alan S. De Jarnette
Michael and Deborah Dean
David DeMattei
Victoria A. Derdivanis
Duane H. Derr
John DeVincenitis
Mike Dianda
Enid K. Dillon
Salvatore E. Dirschberger
Nicholas Donatiello
Paul and Winifred Dooley
Pierre J. Dosogne
Judith A. Dove
Joe Dowling and Siobhan Cleary
Randall G. Drain
Douglas O. Drake
Michael and Bobbie Drukan
Ferrell D. Drum
Robert W. Dusay
Jay P. Duncanson
Patricia Dunne
Marjorie L. Dyer
Jamshid and Mahshid Ehsani
Can and Sevda Elgitz
Thomas Elkinton
John M. Ellenwood
Wafaa El-Sadr, M.D., M.P.H.
Stuart M. Elsberg
Robert J. Elsen
Norman and Susan Ember
Gregg L. Engles
Bess and Ted Enloe
Tucker F. Enthoven
David W. Entsminger
Lucille Z. Epstein
Lance Etcheverry
John Evanetz
Kenneth J. Evanoski
Caroline L. Everts
John and Susan Fabian
William H. Farmer
Gary T. Farrar
James K. Farrell
Jeff and Regen Fearon
Jim Fechtenbaum
Dean R. Feldman
Lawrence and Pauline Feldman
Carla Fendi
Melissa Fetter
Donna Fishel
F. Barron and Rebecca Fletcher
Michael L. Ford
David Frankel
Michael Franklin
Steven J. Frestedt
Tom Freudenheim
Michael A. Fromm and David A. Gonzales
Charlotte Frye
James W. Gallagher
Glenn Galton
Jonathan Gans and Abigail Turin
Joseph Garrett
Robert W. Garthwait, Sr.
John A. Gasoli
Earl C. Gauger
Richard Gere and Carey Lowell
William and Vanessa Getty
Clarice Giles
Raymond and Johnnie Gillespie
Gabriella Forte Glantz
INSTITUTIONAL GIVING

amfAR is grateful to the many institutions large and small that support the fight against AIDS through grants, event sponsorship, cause-related marketing activities and in-kind contributions. Major corporate support comes from business sectors ranging from film, fashion, and fine arts to financial services and pharmaceuticals. Additional generous support is provided by corporate and family foundations and by a wide range of civic associations, social clubs, cooperatives, schools, and churches.

$25,000+

ABC Home Furnishing, Inc.
Angermaier, Brumm & Lange
Unternehmensgruppe Silvia
Quandt
Apparel LLC
Art Fashion Corp.
Asian Century Trading Limited
BATT Corporation
Belisle Foundation
David Bohne Foundation
Bold Films, Inc.
Broadway Cares/Equity Fights AIDS, Inc.
The Calamus Foundation, Inc.
Canal +
Care Label
Cartier, Inc.
Chanel, Inc.
Chopard
Christian Dior Couture
Chubb
Citigroup Inc.
Kenneth Cole Foundation
Concerned Parents for AIDS Research
The Constitution Foundation
Council of Fashion Designers of America
Cynthia Sarkis Perros Production de GRISOGONO
Denise Rich Music, LLC
Dennis Davidson & Associates
The Diller-von Furstenberg Family Foundation
Dior
Dsquarèd2 Srl
Dubai International Film Festival
The Eisner Foundation
Emirates Securities
Estee Lauder, Inc.
Family Health International
Fendi North America, Inc.
Fendi
General Datatech, L.P.
Gianni Versace SpA
GlaxoSmithKline
Goldman Sachs Philanthropy Fund
Hewlett Packard
Hillwood Development Group, L.P.
James C. Hormel Revocable Living Trust
Jimmy Choo
Elton John AIDS Foundation
John Eagle Dealers
JRE GS Trust
The Kanbar Charitable Trust
King Architectural Metals
F.M. Kirby Foundation, Inc.
Leibowitz and Greenway Family Charitable Foundation
Lexington Insurance Company
The Linsey Foundation
Louis Vuitton
M•A•C AIDS Fund
M•A•C Cosmetics France
Macy’s Corporate Services, Inc.
Brian A. McCarthy Foundation
McNeil Management Limited
Melville Capital Limited
Merck & Co., Inc.
Roslyn Milstein Meyer and Jerome Meyer Foundation
Edward L. Milstein Foundation
Missoni SpA
Moët Hennessy
The Ambrose Monell Foundation
Moss Foundation
Neiman Marcus
Once Upon A Time Foundation
Only the Brave Foundation
Open Society Institute
Parfums Christian Dior
Polo Ralph Lauren Europe
The Polo Ralph Lauren Foundation
May Ellen & Gerald Ritter Foundation
Roberto Cavalli SpA
Rock & Republic
Edmond J. Safra Philanthropic Foundation
Sama Dubai LLC
The Schwab Fund for Charitable Giving
Alan D. Schwartz Family Fund
$10,000 - $24,999

- The Aliquot Foundation
- AMC, Inc.
- American Express Company
- Barneys New York
- Benedict Dior Watches
- Bloomberg
- Boehringer Ingelheim
- Pharmaceuticals
- Lewis D. Brounell Charitable Trust
- Burberry
- Cloud 9 of St. Stephen's Church
- Steven A. and Alexandra M. Cohen Foundation
- Communities Foundation of Texas
- Community Technology Foundation of California
- Dallas Market Center
- The Dedman Foundation Fund
- Disney Worldwide Services, Inc.
- Dubai International Capital LLC
- Dubai Investment Group
- The Samuel and Rae Eckman Charitable Foundation
- Frechette Family Foundation
- George Little Management, Inc.
- Giorgio Armani Corporation
- Gold Rush
- The Helene Foundation
- Horchow Family Charitable Trust
- The Karma Foundation
- Laurie Kayden Foundation
- The Kettering Family Foundation
- La Perla
- Carol Anne Levy Foundation
- Liz Claiborne, Inc.
- Audrey Love Charitable Foundation
- Wilhelm and Karl Maybach Foundation
- The Eugene McDermott Foundation
- Mediaset
- Morgans Hotel Group
- Museum Tower
- Newman's Own, Inc.
- Nu Image
- Plasmanet, Inc.
- Prada
- Public Interest Data, Inc.
- Quintessentially
- Adolph and Ruth Schnurmacher Foundation, Inc.
- Sixt GmbH & Co.
- Sunrider Productions II, LLC
- Tom Ford International
- Tonamora Foundation
- Torii Pharmaceutical Company
- U.S. Risk LP
- Vallejo Investments, Inc.
- VAR II, LLC
- Vicini SpA
- Virgin Unite USA, Inc.
- Waldman Bros.
- The Marc Wolinsky and Barry C. Skovgaard Foundation
- World Lodge Limited
- The Xerox Foundation
- The Zankel Fund
- Anonymous (1)

$1,000 - $9,999

- 1000 Madison, LLC
- 42 West LLC
- Abbott Laboratories Fund
- The AEG Family Foundation
- AIDS Fondet
- Ameringer & Yohe Fine Art
- Appelman Schauben
- Fred & Catalina Aranas Family Foundation
- Joseph Arena Charitable Fund
- Armand Diradourian Co Inc.
- Associated Surgeons of Northern NJ, PA
- AT&T California
- Leo H. Bendit Charitable Foundation Trust
- Bloom, Hergott, Diemer & Cook
- BMW Group Italia
- Brandwise, Inc.
- Bridges/Larson Foundation
- Bridgestone/Firestone Trust Fund
- Bruiser on Broadway, LP
- Buddakan New York, LP
- Bungalow, LLC
- Burberry
- Cable Positive, Inc.
- CBK, Ltd., LLC
- Chelsea Eye Associates
- Chi Eta Phi Sorority, Inc.
- CHIS, Inc.
- Church of the Good Shepard - Milford
- Emanuel and Anna Cohen Foundation
- Collegiate Properties Corp.
- Community Foundation of New Jersey
- Corporate Fuel Partners LLC
- The Cowles Charitable Trust
- Crescendo Constellation
- CRR Ventures, LLC
- Burt and Diana Cutler Family Foundation
- Data Electric Corporation
- Davidson Family Charitable Fund
- Discovery Channel
- Donna Karan Company
- Douglas Foundation
- Drummers, Inc
- David or Sindy Durham Investments
- Duro Dyne National Corporation
- The Charlotte S. Dutka Trust
- Dr. Israel Edelstein and Edith Putnam Edelstein Charity Fund
- The Edouard Foundation, Inc.
- Elegant Baby
- Thomas and Jeanne Elmezzi Foundation
- Emerson Network Power Charitable Trust
- Nora Ephron and Nicholas Pileggi Foundation
- Equinox Foundation, Inc.
- Filworks
- Flaxman Family Charitable Trust
- Formosan Mercantile Corporation
- Fortissimo Films
- Fosdick Fund of the New York Community Trust
- Freeman Decorating Company
- Cynthia Frost Charitable Gift Account
- The Abraham Fuchsberg Family Foundation, Inc.
IN-KIND CONTRIBUTIONS

In-kind contributions of goods and services—either donated or discounted—are a mainstay of amfAR’s highly successful benefit events. Ranging from small cocktail parties and store openings to art auctions and international galas, these events play a critical role in raising vital funds and building AIDS awareness.

amfAR relies on generous contributions by individuals and organizations of in-kind gifts ranging from design and printing of invitations and other materials, catering and beverage services, auction and gift bag items, floral arrangements, entertainment, and more.

amfAR also extends its warmest thanks to Kenneth Cole Productions for its many in-kind contributions, including Kenneth Cole products for meetings and conferences, and to American Airlines for the generous donations of air transportation and related services that allow the Foundation to keep travel expenses to a minimum.

Art In-Kind

303 Gallery, New York
511 Gallery, New York
Accolay
Robert Adams
Ricci Albenda
Alexander and Bonin
Jocelyne Alloucherie
Ameringer & Yohe Fine Art
Carl Andre
Andrea Rosen Gallery
Andrew Kreps Gallery
Anthony Meier Fine Arts
Anton Kern Gallery
Kevin Appel
Adam Ball
Barry Whistler Gallery
Robert Beck
Matthew Benedict
Avner Ben-Gal
Harry Bertoia
Betty Cuningham Gallery
bitforms
Black Dragon Society
Blum & Poe
Rosalyn Bodycomb
Tord Boontje
Bortolami
Louise Bourgeois
Troy Brauntuch
Thomas Burke
Stephen Burks
Richmond Burton
James Lee Byars
Ingrid Calame
Suzanne Caporael
Carter
Wendell Castle
Vija Celmins
Jesse Chapman
Charles Cowles Gallery
Cheim & Read
Theresa Chong
Peter Coffin
Collage 20th Century Classics
Anne Collier
George Condo
Bruce Conner
Jessica Craig-Martin
CRG Gallery
Cristina Grajales, Inc.
Danese Gallery
Daum
David Nolan Gallery
David Zwirner, New York
Design Within Reach
Jeremy Dickinson
Tomory Dodge
Dornith Doherty
Dunn and Brown Contemporary
Edward Tyler Nahem Fine Art.
L.L.C.
William Eggleston
Emily Eveleth
Bart Exposito
Evah Fan
Peter Fischli
Tommy Fitzpatrick
Foxy Production
Fraenkel Gallery
Natalie Frank
Friedrich Petzel Gallery
Galerie Chantal Crousel
Galerie EIGEN + ART
Leipzig/Berlin
Galerie Eva Presenhuber
Tim Gardner
Garth Clark Gallery
Gavin Brown’s enterprise
Julie Gilhart
Gladstone Gallery
Michael Goldberg
The Goss-Michael Foundation
Deborah Grant
Greenberg Van Doren Gallery
Guild & Greyshkul
Philip Guston
The Happy Lion

Since the early days of the epidemic, the art community has supported the fight against AIDS with steadfast generosity. amfAR is especially grateful to the many artists, galleries, and museums that have contributed to the resounding success of Two by Two for AIDS and Art, an annual dinner and auction of works by renowned contemporary artists that benefits amfAR and the Dallas Museum of Art. Graciously hosted each year by Howard and Cindy Rachofsky, Two by Two for AIDS and Art has raised more than $21 million since its inception in 1999.

Hauser & Wirth Zürich
Adam Helms
Rebecca Holland
Holly Johnson Gallery
Seonna Hong
Jonathan Horowitz
Tony Horton
Bryan Hunt
Alejandra Icaza
Inman Gallery
Jack Shainman Gallery
Arne Jacobsen
James Cohan Gallery
William E. Jones
Josée Bienvenu Gallery
Roberto Juarez
Mel Kendrick
Lisa Kereszi
Knoedler & Company
Uwe Kowski
Kurimanzutto
Lou Laurita
Jeff Leatham
Lehmann Maupin Gallery
Jean Daniel Lorieux
M
Marco Maggi
Mai 36 Galerie Zürich
The Robert Mapplethorpe Foundation
Marc Foxx
Marian Goodman Gallery
Marianne Boesky Gallery
Edgar Martins
Marty Walker Gallery
Matthew Marks Gallery
Tom McGrath
McKee Gallery
Celeste and Anthony Meier
Metro Pictures
Michael Werner Gallery, New York and Cologne
Mitchell-Innes & Nash
Katya Moran
Jean Luc Moulène
Ted Muehling
Mulcahy Modern
Nicole Klagsbrun Gallery
Norman Parkinson
Limited/Corbis
Adam Ogilvie
Demetrius Oliver
Oliver Kamm/5BE Gallery
Damión Ortega
Tony Oursler
Paula Cooper Gallery
Giuseppe Penone
Simon Periton
Elizabeth Peyton
Danica Phelps
John Pomara
The Public Trust, Dallas
R Gallery
Linda Ridgway
Road Agent
Ugo Rondinone
Susie Rosmarin
Alexander Ross
Thomas Ruff
Runyon Fine Arts
Tom Sachs
Sadie Coles HQ
Sally Rosen 20th Century Collections
Salon 94
Lisa Sanditz
Katia Santibañez
Sara Melitzer Gallery
Lincoln Schatz
Scott + Cooner
Kate Shepherd
Jay Shinn
Allison V. Smith
John Holt Smith
Josh Smith
Keith Sonnier
Ettore Spalletti
Sperone Westwater
Julian Stanczak
Ruby Sterling
Piet Stockmans
Stuart Shave/Modern Art, London
Billy Sullivan
Al Taylor
Mario Testino
Don Van Vliet

General In-Kind

2 West Restaurant
7 W New York
A Gourmet’s Pantry
Al6
Adour Alain Ducasse
Arun Agarwal
Alba Interiors
AllShows.com Premium Ticket Service
Alonzo King’s LINES Ballet
American Airlines
Derek Anderson
Art Basel Miami Beach
Artecnica
Aston Martin of Dallas
Atlantis Events
AVW-TELAV
Azal Emirates Towers
b michael couture
Babies Pet Boutique
Backbone and Wingspan
Banana Republic
Barbuto
Barneys New York
Scott Bass
Bass/Chiarello
Ben E. Keith Company
Benedom Dior Watches
Benoit Restaurant
Bing Bang
Barbara Bjerring
Bloomingdale’s
BLT Burger
BLT Fish Shack
Blue Hill
Blue Ribbon
Blue Smoke
BMW
Bogata Bistro
Bold Films
Bombay Talkie
Bongo
Borgese, Inc.
Bottino
Bouchon
Boulevard Restaurant
Bouley
BR Guest
Bradford Renaissance Portraits
Stephen Brady
Brasserie
Brasserie 8 1/2
Bravo Media
Bread Tribeca
Broadway Cares/Equity Fights
AIDS
Bubble Lounge
Bucks Bounty Restaurant
Buddakan
Susie Tompkins Buell
Barbara Bui
Burberry
The Buzzell Company
William H. Byer
Julie Candice
Care Label
Carolyn Dow Catering
Cartier
Chanel
Chelsea Frames
Dominic Chiarello
Chopard
Christian Dior Couture
Christian Dior Parfums
City Sun Tanning
Margaret Clarrson
Kenneth Cole
Cole Haan
Sean “Diddy” Combs
completely bare
The Container Store
craft dallas
Crema Restaurante
Dallas Market Center
David Barton Gym
de GRISOGONO
Gabrielle de Papp
Dean Mike
Delfina Restaurant
Patrick Demarchelier
DFW Towncar
Discovery Channel
Dubai Duty Free
Dubai International Film Festival
Ducky-Bob’s Party Tent & Rentals
Jennifer and John Eagle
Bob Egan
Elie Saab
Emirates Airline
Empire Baking Co.
Enid Alvarez Photography & Design
Escuelita Night Club
Ottavio and Roberta Fabbri
Michel and Barbara Faure
Fendi
Andrew Fisher
Five Front Street

Chris Vasell
Carlos Vega
Francesco Vezzoli
Cosima von Bonin
The Andy Warhol Foundation for the Visual Arts, Inc.
Marcel Wanders
David Weiss
Brian Wills
Yuh-Shih Wong
Jonas Wood
Yancey Richardson Gallery
Yek
Zach Feuer Gallery
Zwirner & Wirth

42
Floréal
Four Seasons Hotel SF
Francesco Vezzoli
Galeria OMRI
GEORGE Catering
George Little Management
Julie Gilhart
GoGoGear
Mitchell Gold
goldberry
Duncan Graham
Grange Hall
Gucci
Hairspray, The Musical
The Halcyon Company
Harry Winston
Hayden-Harnett
Henrietta Hudson
Herb Ritts Foundation
Hermès of Paris
Julie and Ken Hersh
Hewlett-Packard Company
Homestead General Store
Hotel Fauchère
House of the Muses
Houston’s Restaurant in Preston Center
HurrellPhotos.com
‘inoteca
Cheyenne Jackson
Jewels of Ocean
Jimmy Choo
John Eagle Dealerships
John Eric Sebasta Interiors
John Glen/Equity Enhancers
John Masters Organics
Joseph Cozza Salon
Jumeirah Hotels & Resorts
John Kane
Chef Thomas Keller/Per Se
Kenneth Cole Productions, Inc.
Robin Kert
Kiehl’s Since 1851
Knife + Fork Restaurant & Wine Bar
Korhogo 126
Victor Kubicek
Kuma Inn
Lafo New York
Las Vegas Design Center
Laso Group
Arthur Lauer
Lauren Merkin
Legally Blonde, The Musical
Lever House
Siobhan Liddell
Lipstick Jungle
Lois Lane Travel
Longchamp USA, Inc.
Louis Vuitton
Luhring Augustine
Francis Lutterm
Luxury Limited Edition
M•A•C Cosmetics
Madonna
Marchesa
Mario Testino
Mary’s Fish Camp
Tim Mathiesen
Matthew Christopher
David McShane
Mecca
Michael Kors
Michael’s Restaurant
Mick Rock
Miramax Films
Missoni
Jerry Mitchell
Moët Hennessy USA
Morgans Hotel Group
Morimoto
Morton’s The Steakhouse
The Museum of Modern Art
Neiman Marcus
The New Mel Brooks Musical Young Frankenstein
New York Fitness
Nicholas K
Joseph Nicol
Louis Oliveri
Brian Olsen
Orla Kiely
The Peaks Resort & Golden Door Spa
Prada
Prada USA Corp.
Pschent
Wolfgang Puck
Pure Digital Technologies
Ralph Lauren Home
Brett Ratner
Robert Rauschenberg
Restaurant Florent
Rittenhouse
Vin Roberti
Roberto Cavalli
Rock & Republic
Brian Rodriquez
Rosewood Hotel & Resorts
Rubicon Restaurant
Rubin Museum of Art
Salvatore Ferragamo
San Francisco Symphony
Sand Castle Winery
Sartoria Custom Clothiers
Julian Schnabel
Serendipity 3
Sergio Rossi
Sam & Happy Shipley
Smart Workout, A Specialty Gym
Melanie Smith
Smorgas Chef Midtown
Smorgas Chef West Village
Peter Som
South of France Holiday Villas
Southeast Marketing
Sports Club/LA
Alexa Springs
Spruce
St. Regis Hotel, New York
The Standard, Hollywood
The Stanton Social Restaurant
Star & Stars Clutch
Starwood Hotels
Stella McCartney
Sharon Stone
Jamie & Spook Stream, Donated in Memory of Brooke Aldridge
Strong Travel
Superduluxe
Superfine
T. Edward Wines
Tara Jones Calligraphy
Teatro ZinZanni San Francisco
Michael Tilson Thomas
Tincum Civic Association
Duane Tollison
Wendy Tonkin
Nancy and Mark Toro
Toss Designs
Veronica Toy
The Tribeca Grill
Ivana Trump
Ultimate Limousine NYC
Until There’s a Cure
Vanity Fair
Variable Graphics LLC
Versace
Vice Versa
Victoria’s Secret
Village Restaurant
Visionaire
Dita Von Teese
Vong
VOSS Water
Wakiya
Wallsé
Walnut Street Theatre
Waverly Inn
wd-50
Angie and Skip Weiland
The Weinstein Company
Western Exhibitors, Inc.
Bob Williams
Williams-Sonoma
World Market Center
Xanadu on Broadway
Yves Saint Laurent
Durwood Zedd
Zodax
Zuni Café
Planned Giving

Planned, or deferred, giving is a farsighted investment in the future. Generous bequests and other planned gifts help ensure that amfAR can sustain its support of innovative HIV/AIDS research programs over the long term. Between October 2007 and September 2008, the Foundation was the grateful beneficiary of the planned gifts listed below, including particularly generous legacies from Patrick J. Burnside, Peter H. Meyer, Helen M. Price, Michael Wingate, and Richard W. Weiland.

All Giving Levels

Marcia Altman
Dayton C. Anderson
William Rufus Ayers, Jr.
Bernice R. Baker
Michael F. Bennett
Reginald Thomas Bonanza
Thomas L. Brooke
Mildred Burg
Patrick J. Burnside
Christopher W. Canino
Aaron Cijfer
Max Cole
John Perryman Davidson, III
R. L. Donald Jr.
Gloria F. Dreis
Jean Eastman
Lillian and Frank Fields
Jill and Jayne D. Franklin
A. Lloyd Goode
George H. Graff
James Hawkins
Michael Iannacone
Theodore J. Iwersen
Andrew Kott
Michael Le Clair
Mollie Lipshy
Francisco Martin
John Martinat
Dorothy Merdian
Peter H. Meyer
Margaret W. Midgett
Joan Mills Miller
May M. Moore
Patricia N. Nanon
Robert Eli Paston
Abe Paulson
Jannette E. Powell
Helen M. Price
Lillian Rosenberg
Jennifer Ruth Sachs
Sarah Savin
George C. Scott
Raymond E. Shaheen
Noreen Shapiro
Roland A. Sharp
Joseph L. K. Snyder
Eltise B. Studstill
Rowena I. Sullivan
Stanley M. Takaki
Frances A. Velay
Richard W. Weiland
Thelma and Clyde West
Arthur N. Wiener
Michael Wingate
Joel M. Waldman

Volunteer Support

In addition to the volunteers who generously serve on amfAR’s boards and advisory committees, the Foundation is fortunate to have the support of many committed individuals who offer their time, professional expertise, and financial resources for amfAR’s benefit. In some locales, notably Dallas, Philadelphia/Bucks County, and San Francisco, these dedicated allies have established volunteer steering committees and have organized benefit events that help attract new supporters and build awareness of amfAR’s work.

In addition, amfAR is fortunate to enjoy the support of many celebrities from the fields of art, fashion, film, music, haute cuisine, publishing, and television who generously donate their time and talents to the Foundation’s benefit events. amfAR is especially grateful for the dedicated support of its Founding International Chairman, Dame Elizabeth Taylor, and Sharon Stone, Global Fundraising Chairman, who remain highly visible and effective spokeswomen for the Foundation.

For many years, amfAR has benefited enormously from the steadfast support of two unique volunteer organizations: Concerned Parents for AIDS Research (CPFA) and Bucks County Cabaret.

CPFA

Concerned Parents for AIDS Research (CPFA) was created in 1989 by a group of parents who, spurred by Alison Gertz’s public revelation that she had AIDS, realized that young people everywhere were at risk. CPFA seeks to secure an AIDS-free future by funding basic biomedical and clinical research to develop a preventive vaccine and a cure for HIV/AIDS, and by working to raise AIDS awareness and encouraging parents to become actively involved in finding a solution to this public health crisis. Since its inception, CPFA has raised $6 million for AIDS research.
Bucks County Cabaret

The Greater Philadelphia community was among the first to respond to the AIDS crisis in this country. In 2004, they expanded their membership to include Bucks County. To date, these donors have contributed more than $4.5 million to amfAR, which the Foundation has used to provide grants and fellowships to 80 Philadelphia-area researchers.

Committee Members

- Randy Appar
- Greg Kammerer and Fred White
- David Topel
- Scott Bass
- David McShane
- Allen Black
- Kenneth G. Schaefer
- Bob Egan
- Sam and Happy Shipley

Celebrity Volunteers

- Gael Garcia Bernal
- Lapo Elkann
- Milla Jovovich
- Natalie Portman
- Mary J Blige
- David Furnish
- Diane Kruger
- Lou Reed
- Roberto Bolle
- Terry Gilliam
- Laura Linney
- Natasha Richardson
- Beatrice Carbone
- Danny Glover
- Madonna
- Maggie Rizer
- Dean and Dan Caten (D Squared)
- Eva Green
- Barry Manilow
- Carine Roitfeld
- Kim Cattrall
- Goldie Hawn
- McG
- Rodrigo Santoro
- Eva Cavalli
- Salma Hayek
- Rose McGowan
- Julian Schnabel
- Roberto Cavalli
- Eva Herzigova
- Svetlana Metkina
- Monica Seles
- Jeisa Chiminazzo
- Dennis Hopper
- Margherita Missoni
- Christian Slater
- Sean “Diddy” Combs
- Cheyenne Jackson
- Matthew Modine
- Sharon Stone
- Alan Cumming
- Joshua Jackson
- Petra Nemcova
- Mena Suvari
- Taylor Dayne
- Marc Jacobs
- Michael Pitt
- Stanley Tucci

Workplace Giving

Workplace Giving Programs allow donors to direct a percentage of each paycheck or a fixed dollar amount to amfAR.

Among the many generous individuals who contribute in this way are federal employees and U.S. military personnel who make donations through the Combined Federal Campaign (CFC). amfAR is listed with the CFC as AIDS Research Foundation (amfAR), and our CFC designation number is 11996. amfAR is represented by the CFC by Community Health Charities, a federation of national health agencies. Other donors make their contributions through state and municipal employee campaigns, United Way “write-in” designations, and independent corporate workplace giving programs.

amfAR is deeply grateful to the companies and agencies that allow it to participate in their campaigns and to the many individuals who direct their workplace contributions to the fight against AIDS.
WE ARE PLEASED TO PRESENT THE AUDITED FINANCIAL STATEMENTS of amfAR, The Foundation for AIDS Research, for the fiscal year ending September 30, 2008. This was a period of exciting programmatic expansion for the Foundation, made possible by fundraising growth and careful long-term financial planning. To facilitate further growth, amfAR was able to exceed its ambitious fundraising goals during the year, generating a total of $34.9 million in public support and revenue—a 46.6 percent increase over 2007.

This substantial increase was due in part to a generous bequest of $8.1 million. While it is to be disbursed in eight annual installments, in accordance with GAAP accounting practices, the entire sum was recorded as revenue in 2008. In the absence of the bequest, support and revenue would still have exceeded the prior year’s total by $3.1 million, or 12.5 percent.

Most nonprofits look to two key indicators to gauge operational efficiency and effective use of donor contributions: the supporting services and program spending ratios. Robust revenue growth contributed to a low supporting services ratio of 20.4 percent—the ratio of fundraising and management expenses to total support and revenue (excluding the $8.1 million bequest). Similarly, the program spending ratio remained healthy at 76.9 percent—meaning that 76.9 cents out of every dollar spent was invested directly in vital program activities.

Solid financial growth enabled amfAR to expand the scope and impact of its lifesaving work during 2008. Program spending increased 24.8 percent over the previous year. Twenty-eight new research grants and awards were announced totaling $3.1 million. These included the first round of nine Mathilde Krim Fellowships in Basic Biomedical Research, which are designed to help nurture the next generation of leaders in HIV/AIDS research.

amfAR ended the year with an operating surplus of $11.2 million. In light of the economy’s subsequent downturn in FY09, the financial success of 2008 and the careful stewardship of resources will help safeguard amfAR’s ability to forge ahead with important new program initiatives in 2009 and beyond.

In 2008, amfAR again met the stringent requirements of governance and financial accountability demanded by the Better Business Bureau’s Wise Giving Alliance and the federal government’s workplace fundraising program, the Combined Federal Campaign, as well as many state employee workplace giving campaigns.

A copy of the complete audited financial statements, prepared in accordance with generally accepted accounting principles for not-for-profit organizations as established by the American Institute of Certified Public Accountants, is available upon request from amfAR at 120 Wall Street, 13th Floor, New York, NY 10005.

WALLACE SHEFT, C.P.A.
TREASURER

MICHAEL J. KLINGENSCHMITT
CHAIR
FINANCE & BUDGET COMMITTEE
**Public Support and Revenue**

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PUBLIC SUPPORT</strong></td>
<td>$7,788,531</td>
</tr>
<tr>
<td><strong>SPECIAL EVENTS</strong></td>
<td>$13,212,892</td>
</tr>
<tr>
<td><strong>PLANNED GIVING</strong></td>
<td>$10,069,419</td>
</tr>
<tr>
<td><strong>GOVERNMENT FUNDING</strong></td>
<td>$3,820,447</td>
</tr>
<tr>
<td><strong>INVESTMENT INCOME &amp; OTHER REVENUE</strong></td>
<td>$(7,077)</td>
</tr>
<tr>
<td><strong>Total Public Support &amp; Revenue</strong></td>
<td><strong>$34,874,212</strong></td>
</tr>
</tbody>
</table>

**Expenses**

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RESEARCH</strong></td>
<td>$8,372,638</td>
</tr>
<tr>
<td><strong>GLOBAL INITIATIVES</strong></td>
<td>$5,052,247</td>
</tr>
<tr>
<td><strong>PUBLIC POLICY</strong></td>
<td>$1,446,973</td>
</tr>
<tr>
<td><strong>EDUCATION &amp; INFORMATION</strong></td>
<td>$3,368,097</td>
</tr>
<tr>
<td><strong>Total Program Expenses</strong></td>
<td><strong>$18,240,055</strong></td>
</tr>
<tr>
<td><strong>FUNDRAISING</strong></td>
<td>$3,510,172</td>
</tr>
<tr>
<td><strong>MANAGEMENT &amp; GENERAL</strong></td>
<td>$1,971,856</td>
</tr>
<tr>
<td><strong>Total Supporting Services</strong></td>
<td><strong>$5,482,028</strong></td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$23,722,083</strong></td>
</tr>
</tbody>
</table>

**Assets**

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH &amp; INVESTMENTS</strong></td>
<td>$24,311,311</td>
</tr>
<tr>
<td><strong>PLEDGES &amp; RECEIVABLES, NET</strong></td>
<td>$10,282,345</td>
</tr>
<tr>
<td><strong>PREPAID EXPENSES &amp; OTHER ASSETS</strong></td>
<td>$1,011,454</td>
</tr>
<tr>
<td><strong>MERCHANDISE INVENTORY &amp; DONATED ASSETS</strong></td>
<td>$102,972</td>
</tr>
<tr>
<td><strong>FURNITURE, EQUIPMENT, &amp; LEASEHOLD IMPROVEMENTS, NET</strong></td>
<td>$658,620</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$36,366,702</strong></td>
</tr>
</tbody>
</table>

**Liabilities**

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACCOUNTS PAYABLE &amp; ACCRUED EXPENSES</strong></td>
<td>$1,220,421</td>
</tr>
<tr>
<td><strong>GRANTS &amp; FELLOWSHIPS PAYABLE, NET</strong></td>
<td>$1,960,322</td>
</tr>
<tr>
<td><strong>DEFERRED SUPPORT &amp; REFUNDABLE ADVANCES</strong></td>
<td>$2,409,618</td>
</tr>
<tr>
<td><strong>OTHER LONG-TERM LIABILITIES</strong></td>
<td>$521,536</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$6,111,897</strong></td>
</tr>
</tbody>
</table>

**Net Assets**

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NET ASSETS, BEGINNING OF YEAR</strong></td>
<td>$19,102,676</td>
</tr>
<tr>
<td><strong>Change in Net Assets</strong></td>
<td>$11,152,129</td>
</tr>
<tr>
<td><strong>Net Assets, End of Year</strong></td>
<td><strong>$30,254,805</strong></td>
</tr>
</tbody>
</table>

**Total Liabilities and Net Assets**

<table>
<thead>
<tr>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$36,366,702</strong></td>
</tr>
</tbody>
</table>
LEADERSHIP

MANAGEMENT GROUP

—

As of September 30, 2008

Kevin Robert Frost  
*Chief Executive Officer*

Bradley Jensen  
*Chief Financial Officer*

John F. Logan, Esq.  
*Vice President and General Counsel*

Anthony Ancona  
*Director, Human Resources*

Rowena Johnston, Ph.D.  
*Vice President, Research*

Annette Sohn, M.D.  
*Vice President, Global Initiatives*

Susan J. Blumenthal, M.D., M.P.A  
*Senior Policy and Medical Advisor*

Jeffrey Laurence, M.D.  
*Senior Scientific Consultant for Programs*

BOARD OF TRUSTEES FY2008

—

**Chairman of the Board**

Kenneth Cole  
Chairman

Kenneth Cole Productions

New York, NY

**Treasurer**

Wallace Sheft, C.P.A.  
Partner

Sheft & Co

Westbury, NY

**Founding Chairman**

Mathilde Krim, Ph.D.  
Adjunct Professor

Mailman School of Public Health

Columbia University

New York, NY

**Vice Chairman**

Patricia J. Matson  
Senior Vice President, Communications (ret.)

ABC, Inc.

New York, NY

**Secretary**

Diana L. Taylor  
Managing Director

Wolfensohn & Co. LLC

New York, NY

**Founding International Chairman**

Dame Elizabeth Taylor  
Actress

Bel Air, CA

**Vice Chairman**

John C. Simons  
Managing Partner

Corporate Fuel Partners LLC

New York, NY

**Trustees**

—

Arlen H. Andelson  
Andelson Properties

Los Angeles, CA

Zev Braun  
President & CEO

Braun Entertainment Group, Inc.

Beverly Hills, CA

R. Martin Chavez, Ph.D.  
Managing Director

Goldman, Sachs & Co.

New York, NY

Harry Belafonte  
President

Belafonte Enterprises, Inc.

New York, NY

Jonathan S. Canno  
New York, New York

Jane B. Eisner  
President

The Eisner Foundation

Bel Air, CA

David Bohnett  
Chairman

David Bohnett Foundation

Beverly Hills, CA

Donald Capoccia  
Managing Principal

BFC Partners

Brooklyn, NY
Michael J. Klingensmith  
Managing Director  
AdMedia Partners  
New York, NY

Edward L. Milstein  
Co-Chairman  
Milstein Brothers Capital Partners  
New York, NY

Alan D. Schwartz  
Consultant  
Rothschild, Inc.  
New York, NY

Michele V. McNeill, Pharm.D.  
Chairman  
McNeill Family Foundation  
Long Boat Key, FL

Natasha Richardson†  
Actress  
New York, NY

Kevin Wendle  
Entrepreneur  
New York, NY

Richard H. Metzner  
Chairman & CEO  
Metzner-Schneider Associates  
Dallas, TX

Vincent A. Roberti  
Palisades Pictures  
New York, NY

†Deceased, March 18, 2009

Adjunct Trustees

David E. Bloom, Ph.D.  
Chair, Dept. of Population & International Health  
Harvard School of Public Health  
Boston, MA

Mervyn F. Silverman, M.D., M.P.H.  
President  
Mervyn F. Silverman Associates, Inc.  
Crockett, CA

Mario Stevenson, Ph.D.  
Director, Center for AIDS Research  
University of Massachusetts Medical School  
Worcester, MA

Trustees Emeriti

Arthur J. Ammann, M.D.  
President, Global Strategies for HIV Prevention  
University of California, San Francisco Medical Center  
San Rafael, CA

Arnold W. Klein, M.D.  
Professor of Medicine/Dermatology  
University of California, Los Angeles  
Beverly Hills, CA

Honorary Trustees

Mouna E. Ayoub  
Paris, France

Sandra Hernández, M.D.  
Chief Executive Officer  
The San Francisco Foundation  
San Francisco, CA

The Rev. Dr. Randolph Nugent  
General Secretary (ret.)  
General Board of Global Ministries  
United Methodist Church  
New York, NY

John F. Breglio, Esq.  
Paul, Weiss, Rifkind, Wharton & Garrison  
New York, NY

Sherry Lansing  
Chief Executive Officer/Founder  
The Sherry Lansing Foundation  
Los Angeles, CA

Pauline Phillips  
Nationally Syndicated Columnist (ret.)  
Los Angeles, CA

Robert L. Burkett  
The Carmen Group  
Washington, D.C.

Jane F. Nathanson  
Psychologist  
Chair, Jane & Marc Nathanson Community Foundation  
Los Angeles, CA

Leonard Rabinowitz  
President  
Studio CL  
Los Angeles, CA

Michael Fuchs  
New York, NY
Michael D. Shriver  
Co-Director, AIDS Policy Research Center  
AIDS Research Institute  
University of California, San Francisco  
San Francisco, CA  

Joel D. Weisman, D.O.††  
Physician  
Rancho Mirage, CA  
††Deceased, July 18, 2009

In Memoriam
—
Sheldon W. Andelson, Esq.  
Mrs. Albert D. Lasker  
Jonathan M. Mann, M.D., M.P.H.  
Maxine Mesinger  
Natasha Richardson  
Allan Rosenfield, M.D.  
Peter Scott, Esq.  
Tom Stoddard  
Joel D. Weisman, D.O.

Global Fundraising Chairman
—
Sharon Stone

Program Board
—
Chair  
Allan Rosenfield, M.D.†††  
Dean Emeritus  
Mailman School of Public Health  
Columbia University  
New York, NY

Chair, Global Initiatives Committee  
Mervyn F. Silverman, M.D., M.P.H.  
President  
Mervyn F. Silverman Associates, Inc.  
Crockett, CA

Vice Chair, Global Initiatives Committee  
Adeeba Kamaruzaman, MBBS, FRACP  
Professor  
Head of Infectious Diseases Unit  
Department of Medicine  
University of Malaya  
Kuala Lumpur

Chair, Public Policy Committee  
David E. Bloom, Ph.D.  
Chair, Dept. of Population & International Health  
Harvard School of Public Health  
Boston, MA  
†††Deceased, October 12, 2008

amfAR Ambassadors
—
Milla Jovovich  
Liza Minnelli  
Michelle Yeoh

Vice Chair, Public Policy Committee  
Margaret (Peggy) Hamburg, M.D.  
Vice President for Biological Programs  
Nuclear Threat Initiative  
Washington, D.C.

Chair, Research Committee  
Mario Stevenson, Ph.D.  
Director, Center for AIDS Research  
Professor, Program in Molecular Medicine  
University of Massachusetts Medical School  
Worcester, MA

Vice Chair, Research Committee  
Sherry Deren, Ph.D.  
Director  
Institute for AIDS Research  
Center for Drug Use and HIV Research  
National Development and Research Institutes, Inc.  
New York, NY

Mathilde Krim, Ph.D., ex officio  
Adjunct Professor  
Mailman School of Public Health  
Columbia University  
New York, NY
Members

Dawn Averitt Bridge
Founder
The Well Project
Nellysford, VA

Tim Brown, Ph.D.
Senior Fellow, Population and Health Studies
East-West Center
Honolulu, HI

Alex Carballo-Diéguez, Ph.D.
Associate Professor and Research Scientist
HIV Center for Clinical & Behavioral Studies
New York State Psychiatric Institute
New York, NY

Willard (Ward) Cates, Jr., M.D., M.P.H.
President/Research
Family Health International
Durham, NC

R. Alta Charo, J.D.
Warren P. Knowles Professor of Law & Bioethics
University of Wisconsin Law School
Madison, WI

Grant N. Colfax, M.D.
Director of HIV Prevention & Research
San Francisco Department of Public Health
San Francisco, CA

Hooosen (Jerry) Coovadia, M.D.
Victor Datz Professor of HIV/AIDS Research
Doris Duke Medical Research Institute
Nelson Mandela School of Medicine
University of KwaZulu Natal
Congella, South Africa

Wafaa El-Sadr, M.D., M.P.H.
Chief, Division of Infectious Diseases
Harlem Hospital Center
Professor of Clinical Medicine & Epidemiology
Columbia University
New York, NY

Sherry Glied, Ph.D.
Professor and Chair
Department of Health Policy and Management
Mailman School of Public Health
Columbia University
New York, NY

Jennifer Kates, M.A., M.P.A.
Vice President and Director, HIV Policy
Kaiser Family Foundation
Washington, DC

Patrick Chung-ki Li, M.B.B.S.
Chief of Service
Department of Medicine
Queen Elizabeth Hospital
Hong Kong SAR, China

Kenneth H. Mayer, M.D.
Professor of Medicine & Community Health
Brown University/The Miriam Hospital
Providence, RI

William E. Paul, M.D.
Chief, Laboratory of Immunology
National Institute of Allergy & Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Bethesda, MD

Peter R. Staley
Founder & Editor
AIDSmeds.com
Brooklyn, NY

David Vlahov, Ph.D.
Director
Center for Urban Epidemiological Studies
New York Academy of Medicine
New York, NY

BOARD COMMITTEES

Executive Committee
Kenneth Cole, Chair
Donald A. Capoccia
Michael J. Klingensmith
Mathilde Krim, Ph.D.
Patricia J. Matson
Allan Rosenfield, M.D.††
Wallace Sheft, CPA
John Simons
Diana L. Taylor

Audit Committee
Wallace Sheft, CPA, Chair
John C. Simons
R. Martin Chavez, Ph.D.

Finance & Budget Committee
Michael J. Klingensmith, Chair
Vincent A. Roberti
John C. Simons

Fund Development Committee
Chair (vacant)
Jonathan S. Canno
Edward L. Milstein
Vincent A. Roberti

Board Development Committee
Chair (vacant)
Zev Braun
Jane B. Eisner
Mathilde Krim, Ph.D.
Patricia J. Matson
Alan D. Schwartz

Compensation & Organizational Development Committee
John C. Simons, Chair
Michael J. Klingensmith
Richard H. Metzner

††Deceased, October 12, 2008
Mario Stevenson, Ph.D., Chair
Sherry Deren, Ph.D., Vice Chair
Rafi Ahmed, Ph.D.
Jonathan S. Allan, D.V.M.
Deborah Anderson, Ph.D.
Warren A. Andiman, M.D.
Peter S. Arno, Ph.D.
Larry O. Arthur, Ph.D.
Marcel A. Baluda, Ph.D.
Juan Battle, Ph.D.
Robert B. Belshe, M.D.
Jeanne Bergman, Ph.D.
Samuel A. Bozzette, M.D., Ph.D.
William Burton, M.D.
Dennis R. Burton, Ph.D.
Salvatore T. Butera, D.V.M., Ph.D.
Alex Carballo-Diequez, Ph.D.
Sarah H. Cheeseman, M.D.
David B. Clifford, M.D.
C. Budd Colby, Ph.D.
Grant Colfax, M.D.
Robert L. Cook, M.D., M.P.H.
Deborah Jean Cotton, M.D., M.P.H.
Bryan Richard Cullen, Ph.D.
Susanna Cunningham-Rundles, Ph.D.
Richard Thomas D’Aquila, M.D.
John Delos DeLamater, Ph.D.
Roger Detels, M.D., M.S.
Carl W. Dieffenbach, Ph.D.
Daniel C. Douek, M.D., Ph.D.
D. Peter Droitman, M.D., M.P.H.
Frank Duff, M.D.
Anke A. Ehrhardt, Ph.D.
Homayoon Farzadegan, Ph.D.
Dianne M. Finkelstein, Ph.D.
Jacquelyn H. Flaskerud, Ph.D.
Gerald Herbert Friedland, M.D.
Richard Brian Gaynor, M.D.
Howard E. Gendelman, M.D.
Peter Ghazal, Ph.D.
Thomas Giordano, M.D., M.P.H.
Jean-Charles Grivel, Ph.D.
Roy Gulick, M.D.
Nancy L. Haigwood, Ph.D.
Charles H. Hinkin, Ph.D.
Martin S. Hirsch, M.D.
Sabina Hirshfield, Ph.D.
David Ho, M.D.
Gary Norman Holland, M.D.
Thomas J. Hope, Ph.D.
Shiu-Lok Hu, Ph.D.
David E. Kanouse, Ph.D.
Fahm Kashanchi, Ph.D.
Marcus Kauf, Ph.D.
Ronald C. Kennedy, Ph.D.
Vineet KewalRamani, Ph.D.
Robert Stephen Klein, M.D.
Richard Kornbluth, M.D., Ph.D.
Richard A. Koup, M.D.
Joan Kreiss, M.D., M.S.P.H.
Nathaniel R. Landau, Ph.D.
Alan L. Landay, Ph.D.
Jeffrey Laurence, M.D.
Michael Lederman, M.D.
Sunhee C. Lee, M.D.
Tun-Hou Lee, D.Sc.
Michael J. Leibowitz, M.D., Ph.D.
Carol Levine, M.A.
Robert J. Levine, M.D.
Judy Lieberman, M.D., Ph.D.
H. Kim Lyerly, M.D.
David M. Margolis, M.D.
Martin H. Markowitz, M.D.
Marta L. Marthas, Ph.D.
Kenneth Hugh Mayer, M.D.
Justin C. McArthur, M.B.B.S., M.P.H.
Joseph M. McCune, M.D., Ph.D.
Ian McGowan, M.D., Ph.D.
Michael S. McGrath, M.D., Ph.D.
John Gordon McNeil, M.D., M.P.H.
Donna Mildvan, M.D.
Mathew Mimiaga, Sc.D., M.P.H.
Jay A. Nelson, Ph.D.
Valerie Len Ng, Ph.D., M.D.
Richard Oberhelman, M.D.
Nancy Padian, M.P.H., Ph.D.
Savita Pahwa, M.D.
Tristram G. Parslow, M.D., Ph.D.
Jeremy Paul, Ph.D.
Matija Peterlin, M.D.
Anthony John Pinching, F.R.C.P., D.Phil.
William G. Powderly, M.D., F.R.C.P.
Lynn Pulliam, Ph.D.
Lee Ratner, M.D., Ph.D.
Scott Rhodes, Ph.D., M.P.H., C.H.E.S.
Andrew Rice, Ph.D.
Melissa Robbiana, Ph.D.
Yvonne J. Rosenberg, Ph.D.
Ruth M. Ruprecht, M.D., Ph.D.
Frederick A. Schmitt, Ph.D.
Gerald Schochetman, Ph.D.
Robert Turner Schooley, M.D.
Ola A. Selnes, Ph.D.
Ganes C. Sen, Ph.D.
Enbal Schacham, Ph.D.
Frederick P. Siegal, M.D.
Frangiscos Sifakis, Ph.D., M.P.H.
Gail Skowron, M.D.
Whaijen Soo, M.D., Ph.D.
James L. Sorensen, Ph.D.
Leonidas Stamatatos, Ph.D.
David Strayer, Ph.D.
Klaus Strebel, Ph.D.
Edward Elliot Telzak, M.D.
Ernest F. Terwilliger, Ph.D.
Gwen Van Servellen, R.N., Ph.D., F.A.A.N.
Barbara Visscher, M.D., Dr.P.H.
David Vlahov, Ph.D.
David J. Volsky, Ph.D.
Milton Wainberg, M.D.
Bruce D. Walker, M.D.
Jaime Walkup, Ph.D.
J. Brice Weinberg, M.D.
Steven S. Witkin, Ph.D.
Peter R. Wolfe, M.D.
Richard T. Wyatt, Ph.D.
Huangxi Xiong, M.D.
ACKNOWLEDGMENTS

This annual report was designed by Kelli Anderson, and produced by amfAR’s Public Information department:

Joshua Lamont, Vice President
Andrew McInnes, Group Director, Public Information
Constance Herndon, Senior Staff Writer
Carolyn Hanson, Staff Writer

Winnie McCroy, Staff Writer

Special thanks to Sue Doster, Yolande Hunter, Joseph Isahack,
Katherine Rumph, and Raoul Tenazas

New York
amfAR
120 Wall Street, 13th Floor
New York, NY 10005-3908
(212) 806-1600 (tel)
(212) 806-1601 (fax)

Bangkok, Thailand
TREAT Asia
Exchange Tower
388 Sukhumvit Road, Suite 2104
Klongtoey, Bangkok 10110
Thailand
+66 (0)2 663 7561 (phone)
+66 (0)2 663 7562 (fax)

Washington, D.C.
amfAR
1150 17th Street, NW
Suite 406
Washington, DC 20036-4622
(202) 331-8600 (tel)
(202) 331-8606 (fax)

USA TOLL-FREE NUMBER
1-800-39-amfAR

www.amfAR.org

amfAR, The Foundation for AIDS Research, is a New York State not-for-profit corporation and is exempt from federal income tax under Section 501(c)(3) of the United States Internal Revenue Code (“the code”) and corresponding New York Revenue and Taxation code sections. Contributions to amfAR are tax-deductible in accordance with the code.

amfAR meets the BBB Wise Giving Alliance’s Standards for Charity Accountability

AMERICAN AIRLINES is the official airline of amfAR.